2016 ESC/EAS Guidelines for the Management of Dyslip

Atherosclerosis

253, 281-344

DOI: 10.1016/j.atherosclerosis.2016.08.018

Citation Report

#	Article	IF	Citations
1	Poly-ADP-ribosylation in health and disease. Cellular and Molecular Life Sciences, 2005, 62, 731-738.	2.4	50
2	Poly-ADP-ribosylation in health and disease. Cellular and Molecular Life Sciences, 2005, 62, 739-750.	2.4	115
3	Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia. Clinical Pharmacology: Advances and Applications, 2017, Volume 9, 1-7.	0.8	6
4	Integrative mutation, haplotype and Gâ€‰Ã—â€‰G interaction evidence connects ABGL4, LRP8 and PCSK9 genes to cardiometabolic risk. Scientific Reports, 2016, 6, 37375.	1.6	5
6	Reply to: â€œStatins probably do not cause cataractsâ€• Atherosclerosis, 2016, 254, 311-312.	0.4	0
7	Statins for primary prevention of cardiovascular disease. BMJ, The, 2016, 355, i6334.	3.0	12
9	Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8Âyears follow up study. Cardiovascular Diabetology, 2016, 15, 147.	2.7	6
10	Evolving Approaches for Statins in Primary Prevention. JAMA - Journal of the American Medical Association, 2016, 316, 1981.	3.8	4
11	Dose wisely! How lipid-lowering undertreatment can lead to overtreatment. Atherosclerosis, 2016, 255, 126-127.	0.4	3
13	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 195-203.e4.	0.6	56
14	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. Current Cardiology Reports, 2017, 19, 7.	1.3	42
15	Palm oil and human health. Meeting report of NFI: Nutrition Foundation of Italy symposium. International Journal of Food Sciences and Nutrition, 2017, 68, 643-655.	1.3	27
16	Evidence-based goals in LDL-C reduction. Clinical Research in Cardiology, 2017, 106, 237-248.	1.5	69
19	Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nature Reviews Nephrology, 2017, 13, 297-310.	4.1	219
20	Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study). Atherosclerosis, 2017, 259, 20-25.	0.4	34
21	Predicting Cardiovascular Events in Familial Hypercholesterolemia. Circulation, 2017, 135, 2133-2144.	1.6	270
22	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: Clinical and Experimental, 2017, 71, 17-32.	1.5	208
23	2017 Taiwan lipid guidelines for high risk patients. Journal of the Formosan Medical Association, 2017, 116, 217-248.	0.8	123

#	Article	IF	Citations
24	Glycemic index is as reliable as macronutrients on food labels. American Journal of Clinical Nutrition, 2017, 105, 768-769.	2.2	15
26	Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemiaÂ(a). Clinical Research in Cardiology Supplements, 2017, 12, 22-26.	2.0	5
27	Lipoprotein(a) in nephrological patients. Clinical Research in Cardiology Supplements, 2017, 12, 27-30.	2.0	5
28	Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines. Clinical Research in Cardiology Supplements, 2017, 12, 38-43.	2.0	19
29	Pathophysiology and treatment of atherosclerosis. Netherlands Heart Journal, 2017, 25, 231-242.	0.3	186
30	Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension. Scientific Reports, 2017, 7, 41650.	1.6	24
31	Food and plant bioactives for reducing cardiometabolic disease: How does the evidence stack up?. Trends in Food Science and Technology, 2017, 69, 192-202.	7.8	22
32	Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2017, 29, 86-91.	0.1	5
33	Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. European Heart Journal, 2017, 38, 2264-2276.	1.0	94
34	Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes. Current Cardiology Reports, 2017, 19, 48.	1.3	13
35	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2017, 38, 2459-2472.	1.0	2,292
36	Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor Î± modulator (SPPARMÎ±), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis, 2017, 261, 144-152.	0.4	101
37	Alirocumab for the treatment of hypercholesterolaemia. Expert Review of Clinical Pharmacology, 2017, 10, 571-582.	1.3	9
38	Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10â€year period: an observational study. Diabetic Medicine, 2017, 34, 1244-1251.	1.2	8
39	The efficacy of evolocumab in the management of hyperlipidemia: a systematic review. Therapeutic Advances in Cardiovascular Disease, 2017, 11, 155-169.	1.0	8
41	Consumption of seafood and its estimated heavy metals are associated with lipid profile and oxidative lipid damage on healthy adults from a Spanish Mediterranean area: A cross-sectional study. Environmental Research, 2017, 156, 644-651.	3.7	21
43	Management of Dyslipidemias in Europe and the USA: Same Evidence, Different Conclusions? Can We Find Common Ground?. Current Cardiology Reports, 2017, 19, 49.	1.3	2
44	Practical aspects in the management of statin-associated muscle symptoms (SAMS). Atherosclerosis Supplements, 2017, 26, 45-55.	1.2	21

#	Article	IF	Citations
45	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Metabolism: Clinical and Experimental, 2017, 74, 43-46.	1.5	19
46	Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. European Heart Journal, 2017, 38, 2490-2498.	1.0	161
47	A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. European Heart Journal, 2017, 38, 1823-1831.	1.0	66
48	The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. European Heart Journal, 2017, 38, 2499-2507.	1.0	176
49	Statin Prescribing Practices in the Comprehensive Care for HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, e26-e29.	0.9	18
50	Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. Cardiovascular Drugs and Therapy, 2017, 31, 187-195.	1.3	19
51	Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open, 2017, 7, e013851.	0.8	21
52	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	5.5	84
53	Statins for Primary Prevention of Cardiovascular Disease. Medical Clinics of North America, 2017, 101, 689-699.	1.1	53
55	Coronary artery disease and arrhythmias. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 69-70.	1.4	6
56	Investigational therapies for hypercholesterolemia. Expert Opinion on Investigational Drugs, 2017, 26, 603-617.	1.9	4
57	Reply to: â€œAppropriate use of cholesterol-lowering therapyâ€• Atherosclerosis, 2017, 262, 200-201.	0.4	0
58	How to measure the net benefit of treatment?. Therapie, 2017, 72, 51-61.	0.6	3
59	Chronic physical illnesses in patients with schizophrenia spectrum disorders are independently associated with higher rates of psychiatric rehospitalization; a cross-sectional study in Croatia. European Psychiatry, 2017, 43, 73-80.	0.1	21
60	Integrative variants, haplotypes and diplotypes of the CAPN3 and FRMD5 genes and several environmental exposures associate with serum lipid variables. Scientific Reports, 2017, 7, 45119.	1.6	13
61	Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. Scientific Reports, 2017, 7, 45788.	1.6	12
62	Galectin-3 binding protein, coronary artery disease and cardiovascular mortality: Insights from the LURIC study. Atherosclerosis, 2017, 260, 121-129.	0.4	26
63	Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. European Heart Journal, 2017, 38, 1832-1839.	1.0	97

#	Article	IF	Citations
64	PPAR-Î± agonists are still on the rise: an update on clinical and experimental findings. Expert Opinion on Investigational Drugs, 2017, 26, 593-602.	1.9	44
65	Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2017, 24, 1051-1059.	0.8	24
66	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology, 2017, 105, 266-280.	1.2	122
67	Cashew consumption reduces total and LDL cholesterol: a randomized, crossover, controlled-feeding trial ,. American Journal of Clinical Nutrition, 2017, 105, 1070-1078.	2.2	54
68	NMR-Based Lipid Profiling of High Density Lipoprotein Particles in Healthy Subjects with Low, Normal, and Elevated HDL-Cholesterol. Journal of Proteome Research, 2017, 16, 1605-1616.	1.8	21
69	Statins for primary prevention of cardiovascular disease. Heart, 2017, 103, 477-478.	1.2	5
70	Hypertriglyceridaemia and risk of coronary artery disease. Nature Reviews Cardiology, 2017, 14, 401-411.	6.1	257
71	Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie SocietÃ Italiana di Medicina) Tj ETQq1 1 0.784314 rgBT /Ov	1.2	8
72	Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. Circulation, 2017, 135, 338-351.	1.6	80
73	A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. Atherosclerosis Supplements, 2017, 24, 1-15.	1.2	83
74	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. Advances in Therapy, 2017, 34, 300-323.	1.3	37
75	Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study. European Heart Journal, 2017, 38, 3560-3566.	1.0	171
76	Effects of Vitamin D on Blood Pressure, Arterial Stiffness, and Cardiac Function in Older People After 1ÂYear: BESTâ€Ð (Biochemical Efficacy and Safety Trial of Vitamin D). Journal of the American Heart Association, 2017, 6, .	1.6	30
77	Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease. European Heart Journal Quality of Care & Clinical Outcomes, 2017, 3, 281-288.	1.8	2
78	The study of familial hypercholesterolemia in Italy: A narrative review. Atherosclerosis Supplements, 2017, 29, 1-10.	1.2	16
79	Not Every Coronary Artery Calcium Is the Same. Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	0
80	Low Very low-Density Lipoprotein Cholesterol but High Very low-Density Lipoprotein Receptor mRNA Expression in Peripheral White Blood Cells: An Atherogenic Phenotype for Atherosclerosis in a Community-Based Population. EBioMedicine, 2017, 25, 136-142.	2.7	7
81	Peripheral Arterial Disease and Chronic Kidney Disease. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2017, 38, 29-33.	0.2	3

#	Article	IF	Citations
82	Relation of Lowâ€Density Lipoprotein Cholesterol With Microvascular Injury and Clinical Outcome in Revascularized STâ€Elevation Myocardial Infarction. Journal of the American Heart Association, 2017, 6, .	1.6	37
83	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutrition Reviews, 2017, 75, 731-767.	2.6	238
84	Comparative effects of organic, traditional, and intensive production with probiotics on the fatty acid profile of cowâ€™s milk. Journal of Food Composition and Analysis, 2017, 63, 157-163.	1.9	14
85	Association of Frequency of Lipid Testing With Changes in Lipid-Lowering Therapy. JAMA Internal Medicine, 2017, 177, 1529.	2.6	1
86	Suboptimal use of statins for secondary cardiovascular prevention: a â€œplanetaryâ€•issue. Internal and Emergency Medicine, 2017, 12, 1091-1092.	1.0	0
87	Strategies for the use of nonstatin therapies. Current Opinion in Lipidology, 2017, 28, 458-464.	1.2	2
88	Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1099-1104.	1.5	16
89	Novel treatment options for the management of heterozygous familial hypercholesterolemia. Expert Review of Clinical Pharmacology, 2017, 10, 1375-1381.	1.3	12
90	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 941-950.	5.5	452
91	Alirocumab Treatment and Achievement of Nonâ€Highâ€Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. Journal of the American Heart Association, 2017, 6, .	1.6	14
92	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above. Circulation, 2017, 136, 1878-1891.	1.6	144
93	Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study. BMJ Open, 2017, 7, e014427.	0.8	5
94	Recomendaciones prÃ¡cticas para el manejo del riesgo cardiovascular asociado a la dislipemia aterogÃ©nica, con especial atenciÃ³n al riesgo residual. AdaptaciÃ³n espaÃ±ola de un Consenso Europeo de Expertos. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2017, 29, 168-177.	0.4	8
95	Hypertriglyceridemia, an Underestimated Cardiovascular Risk Factor: An Epidemiological Study of the Rome Area. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 401-404.	1.0	3
96	The FOURIER study: The profound study of Nature is the most fertile source of discovery. Hellenic Journal of Cardiology, 2017, 58, 146-147.	0.4	3
97	Tratamiento de la angina estable. Medicine, 2017, 12, 2163-2173.	0.0	0
98	Moderate alcohol consumption and atherosclerosis. Wiener Klinische Wochenschrift, 2017, 129, 835-843.	1.0	25
99	Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2017, 29, 168-177.	0.1	1

#	Article	IF	Citations
100	Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family. Atherosclerosis, 2017, 264, 58-66.	0.4	6
101	The preference of the physicians in diagnosis and treatment of cardiovascular diseases. International Journal of the Cardiovascular Academy, 2017, 3, 11-15.	0.1	1
103	Cholesterol Management in the Era of PCSK9 Inhibitors. Current Cardiology Reports, 2017, 19, 83.	1.3	4
104	Reporting LDL-cholesterol levels in the era of intensive lipid management: a clarion call. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1447-1449.	1.4	5
105	Obesity, Hypertension, and Dyslipidemia. Endocrinology, 2017, , 1-15.	0.1	2
106	Association of the TG/HDL-C and Non-HDL-C/HDL-C Ratios with Chronic Kidney Disease in an Adult Chinese Population. Kidney and Blood Pressure Research, 2017, 42, 1141-1154.	0.9	29
108	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1082.	0.4	189
109	LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China. Medicine (United States), 2017, 96, e8555.	0.4	13
110	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. Journal of the American Heart Association, 2017, 6, .	1.6	29
111	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin. JAMA Cardiology, 2017, 2, 1385.	3.0	89
112	Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids. Current Atherosclerosis Reports, 2017, 19, 60.	2.0	32
113	Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. European Journal of Preventive Cardiology, 2017, 24, 1383-1401.	0.8	43
114	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2017, 18, 1243-1260.	0.9	35
115	Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial. Advances in Therapy, 2017, 34, 1966-1975.	1.3	26
117	Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS II Study in Egypt. Cardiology and Therapy, 2017, 6, 105-120.	1.1	3
119	Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype. Current Cardiology Reports, 2017, 19, 61.	1.3	12
120	Longâ€Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening. Journal of the American Heart Association, 2017, 6, .	1.6	14
121	Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovascular Disorders, 2017, 17, 160.	0.7	80

#	Article	IF	Citations
122	Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study. BMC Cardiovascular Disorders, 2017, 17, 166.	0.7	12
123	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovascular Diabetology, 2017, 16, 70.	2.7	25
124	Non-high-density lipoprotein cholesterol predicts nonfatal recurrent myocardial infarction in patients with ST segment elevation myocardial infarction. Lipids in Health and Disease, 2017, 16, 20.	1.2	24
125	Observational Prospective study to esTIMAte the rates of outcomes in patients undergoing PCI with drug-eluting stent implantation who take statins â€“follow-up (OPTIMA II). Current Medical Research and Opinion, 2017, 33, 253-259.	0.9	0
126	Guidelineâ€based statin/lipidâ€lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multiâ€Ethnic Study of Atherosclerosis (<scp>MESA</scp>). Clinical Cardiology, 2017, 40, 163-169.	0.7	7
127	Lipoprotein(a) and the Apolipoprotein B/A1 Ratio Independently Associate With Surgery for Aortic Stenosis Only in Patients With Concomitant Coronary Artery Disease. Journal of the American Heart Association, 2017, 6, .	1.6	23
128	Statins for the Prevention of Acute Pancreatitis. American Journal of Gastroenterology, 2017, 112, 1765-1767.	0.2	19
129	ANMCO Scientific Statement: clinical management of hypercholesterolaemia in patients with acute coronary syndromes. European Heart Journal Supplements, 2017, 19, D64-D69.	0.0	2
130	ANMCO Position Paper: diagnosticâ€therapeutic pathway in patients with hypercholesterolaemia and statin intolerance. European Heart Journal Supplements, 2017, 19, D55-D63.	0.0	7
131	Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*. Journal of Market Access & Health Policy, 2017, 5, 1412753.	0.8	7
132	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. Journal of the American College of Cardiology, 2017, 70, 1290-1301.	1.2	162
133	Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPICâ€Heidelberg cohort. BMC Medicine, 2017, 15, 218.	2.3	78
134	The Adherence Rate Threshold is Drug Specific. Drugs in R and D, 2017, 17, 645-653.	1.1	18
135	Is the addition of fish oil to statin therapy in patients with persistent hypertriglyceridemia more effective than statins alone?. Evidence-Based Practice, 2017, 20, E12.	0.0	0
136	Familial Hypercholesterolemia: A Systematic Review of Guidelines on Genetic Testing and Patient Management. Frontiers in Public Health, 2017, 5, 252.	1.3	34
137	Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT	1.0	14
138	Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. Drug Design, Development and Therapy, 2017, Volume 11, 3461-3469.	2.0	14
139	Progression of coronary artery disease in a HIV-infected patient previously treated for ascending aorta aneurysm. Kardiochirurgia I Torakochirurgia Polska, 2017, 3, 211-213.	0.1	1

#	Article	IF	Citations
141	Cardiovascular Screening for the Asymptomatic Patient with Diabetes: More Cons Than Pros. Journal of Diabetes Research, 2017, 2017, 1-19.	1.0	16
142	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Archives of Medical Science, 2017, 5, 965-1005.	0.4	206
143	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Archives of Medical Science, 2017, 1, 1-45.	0.4	70
144	The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis. International Journal of Molecular Sciences, 2017, 18, 1260.	1.8	28
145	Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. Vascular Health and Risk Management, 2017, Volume 13, 343-351.	1.0	14
146	Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry. PLoS ONE, 2017, 12, e0182687.	1.1	11
147	Annexin A5 reduces early plaque formation in ApoE -/- mice. PLoS ONE, 2017, 12, e0190229.	1.1	15
149	Control of cardiovascular risk factors and its determinants in the general populationâ€“ findings from the STAAB cohort study. BMC Cardiovascular Disorders, 2017, 17, 276.	0.7	24
150	Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovascular Diabetology, 2017, 16, 124.	2.7	107
151	Lipid management in India: a nationwide, cross-sectional physician survey. Lipids in Health and Disease, 2017, 16, 130.	1.2	9
152	Hypertriglyceridemia and atherosclerosis. Lipids in Health and Disease, 2017, 16, 233.	1.2	163
153	Effect of a short-term dietary supplementation with phytosterols, red yeast rice or both on lipid pattern in moderately hypercholesterolemic subjects: a three-arm, double-blind, randomized clinical trial. Nutrition and Metabolism, 2017, 14, 61.	1.3	34
154	The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials, 2017, 18, 316.	0.7	4
155	Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial. Trials, 2017, 18, 501.	0.7	8
156	Prevalence and determinants of polypharmacy in Switzerland: data from the CoLaus study. BMC Health Services Research, 2017, 17, 840.	0.9	50
157	Coronary Heart Disease Risk in Patients with Schizophrenia: A Lebanese Cross-Sectional Study. Journal of Comorbidity, 2017, 7, 79-88.	3.9	9
158	Current guidelines on prevention with a focus on dyslipidemias. Cardiovascular Diagnosis and Therapy, 2017, 67, S4-S10.	0.7	13
159	Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 1270-1276.	0.5	15

#	Article	IF	Citations
160	Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1555-1562.	0.9	18
161	Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report. American Journal of Case Reports, 2017, 18, 1238-1241.	0.3	18
162	Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Journal of Thoracic Disease, 2017, 9, 1345-1352.	0.6	6
163	Vaccine against PCSK9: the natural strategy from passive to active immunization for the prevention of atherosclerosis. Journal of Thoracic Disease, 2017, 9, 4291-4294.	0.6	6
164	Phytosterols in the Treatment of Hypercholesterolemia and Prevention of Cardiovascular Diseases. Arquivos Brasileiros De Cardiologia, 2017, 109, 475-482.	0.3	93
165	Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors. European Cardiology Review, 2017, 12, 30.	0.7	0
166	Family Physician-Led Group Visits for Lifestyle Modification in Women with Weight Problems: A Pilot Intervention and Follow-Up Study. Obesity Facts, 2018, 11, 1-14.	1.6	11
167	Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes. Diabetes Care, 2018, 41, 1244-1250.	4.3	16
168	Statin Intolerance. Cardiology Clinics, 2018, 36, 225-231.	0.9	36
169	Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis. Clinical Cardiology, 2018, 41, 378-384.	0.7	36
170	Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemiaâ€"target attainment requires further increase of intensity. Pediatric Nephrology, 2018, 33, 1199-1208.	0.9	12
171	Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease. Journal of Clinical Lipidology, 2018, 12, 597-603.e1.	0.6	31
172	Standardization of laboratory lipid profile assessment: A call for action with a special focus on the 2016 ESC/EAS dyslipidemia guidelines â€" Executive summary. Revista Portuguesa De Cardiologia, 2018, 37, 279-283.	0.2	4
173	Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors. Nutrition and Diabetes, 2018, 8, 24.	1.5	15
174	Percutaneous Closure of Left Atrial Appendage significantly affects Lipidome Metabolism. Scientific Reports, 2018, 8, 5894.	1.6	5
175	Association between fasting Triglyceride levels and the Prevalence of Asymptomatic Intracranial Arterial Stenosis in a Chinese Community-based Study. Scientific Reports, 2018, 8, 5744.	1.6	8
176	Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner. Surgery for Obesity and Related Diseases, 2018, 14, 769-779.	1.0	14
177	Effects of a novel selective peroxisome proliferatorâ€activated receptorâ€Î± modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. Journal of Diabetes Investigation, 2018, 9, 1323-1332.	1.1	32

#	Article	IF	Citations
178	Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems. Drug Safety, 2018, 41, 745-752.	1.4	24
179	Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease. European Heart Journal, 2018, 39, 2172-2178.	1.0	53
180	Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients. Revista Espanola De Cardiologia (English Ed), 2018, 71, 1010-1017.	0.4	10
181	Documento de consenso. Manejo de la enfermedad hepÃ¡tica grasa no alcohÃ³lica (EHGNA). GuÃa de prÃ¡ctica clÃnica. GastroenterologÃa Y HepatologÃa, 2018, 41, 328-349.	0.2	71
182	Statin loading in cardiovascular surgery. Current Opinion in Cardiology, 2018, 33, 436-443.	0.8	27
183	Hemodialysisâ€induced cardiovascular disease. Seminars in Dialysis, 2018, 31, 258-267.	0.7	97
184	Cardiovascular Risk Factors and Peripheral Arterial Disease. , 2018, , 189-200.		0
186	Lipid discordance and carotid plaque in obese patients in primary prevention. EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed), 2018, 65, 39-44.	0.1	0
187	Obesity and cardiovascular risk. Journal of Hypertension, 2018, 36, 1427-1440.	0.3	86
188	Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?. Cardiology Clinics, 2018, 36, 287-298.	0.9	13
189	Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. European Heart Journal, 2018, 39, 354-359.	1.0	43
190	Update of green tea interactions with cardiovascular drugsÂandÂputative mechanisms. Journal of Food and Drug Analysis, 2018, 26, S72-S77.	0.9	39
191	Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials. Journal of Clinical Lipidology, 2018, 12, 277-291.e3.	0.6	19
192	Lipid Testing and Statin Dosing After Acute Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	1.6	22
193	PCSK9 inhibition for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia. The Cochrane Library, 0, , .	1.5	0
195	Advances in lipid-lowering therapy through gene-silencing technologies. Nature Reviews Cardiology, 2018, 15, 261-272.	6.1	101
196	PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis, 2018, 270, 187-188.	0.4	32
197	The pharmacological management of metabolic syndrome. Expert Review of Clinical Pharmacology, 2018, 11, 397-410.	1.3	80

#	Article	IF	Citations
198	The challenge of risk prediction: How good are we?. European Journal of Preventive Cardiology, 2018, 25, 418-419.	0.8	4
199	Guidance for the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health. EFSA Journal, 2018, 16, e05136.	0.9	50
200	Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 33-54.	2.7	20
201	Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clinical Research in Cardiology, 2018, 107, 380-388.	1.5	59
202	Discordancia lipÃ¡dica y placa carotÃ¡dea en pacientes obesos en prevenciÃ³n primaria. Endocrinologia, Diabetes Y NutriciÃ“n, 2018, 65, 39-44.	0.1	0
203	Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy. Journal of Clinical Lipidology, 2018, 12, 409-416.	0.6	31
204	Beyond the traditional lipid parameters in chronic kidney disease. Nefrologia, 2018, 38, 109-113.	0.2	4
205	Management of diabetes in older adults. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 206-218.	1.1	47
206	NÃºmero de pacientes candidatos a recibir inhibidores de la PCSK9 segÃºn datos de 2,5 millones de participantes de la prÃ¡ctica clÃnica real. Revista Espanola De Cardiologia, 2018, 71, 1010-1017.	0.6	23
208	Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia. International Journal of Cardiology, 2018, 255, 215-220.	0.8	6
209	The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE ITâ€“TIMI 22. Clinical Cardiology, 2018, 41, 68-73.	0.7	5
210	Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey. International Journal of Cardiology, 2018, 252, 193-198.	0.8	34
211	Appropriateness of statin prescription in the elderly. European Journal of Internal Medicine, 2018, 50, 33-40.	1.0	43
212	Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 5-7.	1.0	0
213	Management of Statin Intolerance in 2018: Still More Questions Than Answers. American Journal of Cardiovascular Drugs, 2018, 18, 157-173.	1.0	130
214	Health promotion: A step beyond prevention in cardiology. American Heart Journal, 2018, 198, 178-179.	1.2	0
215	Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs, 2018, 78, 215-229.	4.9	33
216	Effects of Pemafibrate, a Novel Selective PPARÎ± Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Diabetes Care, 2018, 41, 538-546.	4.3	122

#	Article	IF	Citations
217	Adverse effects of statin therapy: perception vs. the evidence â€“ focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	1.0	262
218	Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan. Journal of Atherosclerosis and Thrombosis, 2018, 25, 580-592.	0.9	13
219	Assessing Impact of High-Dose Pitavastatin on Carotid Artery Elasticity with Speckle-Tracking Strain Imaging. Journal of Atherosclerosis and Thrombosis, 2018, 25, 1137-1148.	0.9	6
220	Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis. Cardiology, 2018, 140, 30-34.	0.6	5
221	Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). European Heart Journal, 2018, 39, 2401-2408.	1.0	383
222	<scp>ESRD</scp>â€induced dyslipidemiaâ€”Should management of lipid disorders differ in dialysis patients?. Seminars in Dialysis, 2018, 31, 398-405.	0.7	19
223	How does the TRS 2Â°P score relate to real-world patients?. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 72-74.	1.4	5
224	Multivariate analysis for coronary heart disease in heterozygote familial hypercholesterolemia patients. Personalized Medicine, 2018, 15, 87-92.	0.8	4
225	Improving long-term adherence to statin therapy: a qualitative study of GPsâ€™ experiences in primary care. British Journal of General Practice, 2018, 68, e401-e407.	0.7	15
226	Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits. Circulation Journal, 2018, 82, 937-943.	0.7	15
227	Lipids and Lipoproteins in Risk Prediction. Cardiology Clinics, 2018, 36, 213-220.	0.9	7
228	Proprotein Convertase Subtilisin Kexin 9 Inhibitors. Cardiology Clinics, 2018, 36, 241-256.	0.9	5
229	HIV infection and lipids. Current Opinion in Cardiology, 2018, 33, 429-435.	0.8	7
230	Molecular association model of PPARÎ± and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMÎ±. Biochemical and Biophysical Research Communications, 2018, 499, 239-245.	1.0	47
231	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer. Journal of Clinical Lipidology, 2018, 12, 826-829.	0.6	5
232	Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: A subgroup analysis from the PAPA-CAD study. Journal of International Medical Research, 2018, 46, 1902-1909.	0.4	7
233	Implications of the Mediterranean diet and physical exercise on the lipid profile of metabolically healthy obese women as measured by nuclear magnetic resonance spectroscopy (1 H NMR). Chemistry and Physics of Lipids, 2018, 213, 68-75.	1.5	8
234	Managing dyslipidaemia for the primary prevention of cardiovascular disease. BMJ: British Medical Journal, 2018, 360, k946.	2.4	9

#	Article	IF	Citations
235	Prognostic Impact of Statin Intensity in Heart Failure Patients With Ischemic Heart Disease: A Report From the CHARTâ€2 (Chronic Heart Failure Registry and Analysis in the Tohoku District 2) Study. Journal of the American Heart Association, 2018, 7, .	1.6	12
236	Trends in BMI, Glycemic Control and Obesity-Associated Comorbidities After Explantation of the Duodenal-Jejunal Bypass Liner (DJBL). Obesity Surgery, 2018, 28, 2187-2196.	1.1	8
237	Statin Therapy in Patients Undergoing Coronary Artery Bypass Grafting for Acute Coronary Syndrome. Thoracic and Cardiovascular Surgeon, 2018, 66, 434-441.	0.4	4
238	Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. Critical Reviews in Food Science and Nutrition, 2018, 58, 2549-2556.	5.4	60
239	PCSK9 and infection: A potentially useful or dangerous association?. Journal of Cellular Physiology, 2018, 233, 2920-2927.	2.0	26
240	MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?. Clinical Reviews in Allergy and Immunology, 2018, 54, 224-233.	2.9	27
241	Statin Therapy and Risk of Diabetes Mellitus in Aging Patients With Heterozygous Familial Hypercholesterolemia or Familial Combined Hyperlipidemia: A 10-Year Follow-Up. Angiology, 2018, 69, 242-248.	0.8	9
242	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2018, 39, 119-177.	1.0	7,100
243	Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis. Genetics in Medicine, 2018, 20, 591-598.	1.1	86
244	Calcification of coronary arteries in early rheumatoid arthritis prior to anti-rheumatic therapy. Rheumatology International, 2018, 38, 211-217.	1.5	8
247	Impact of malondialdehyde-modified low-density lipoprotein on coronary plaque vulnerability in patients not receiving lipid-lowering therapy: a whole coronary analysis with multislice-computed tomography. Heart and Vessels, 2018, 33, 351-357.	0.5	7
248	Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Populationâ€Based Cohort Study. Clinical Pharmacology and Therapeutics, 2018, 104, 719-732.	2.3	12
249	Usefulness of the Martin Method for Estimation of Low-Density Lipoprotein Cholesterol in Coronary Atherosclerosis. Medical Principles and Practice, 2018, 27, 8-14.	1.1	14
250	Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review. Current Medical Research and Opinion, 2018, 34, 459-473.	0.9	27
251	MÃ¡s allÃ¡ de los parÃ¡metros lipÃdicos tradicionales en la enfermedad renal crÃ³nica. Nefrologia, 2018, 38, 109-113.	0.2	5
252	A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT). Journal of Clinical Lipidology, 2018, 12, 162-172.e6.	0.6	42
253	A case of sitosterolemia misdiagnosed as familial hypercholesterolemia: A 4-year follow-up. Journal of Clinical Lipidology, 2018, 12, 236-239.	0.6	19
254	The reverse metabolic syndrome in the elderly: Is it a â€œcatabolicâ€•syndrome?. Aging Clinical and Experimental Research, 2018, 30, 547-554.	1.4	13

#	Article	IF	Citations
256	ST segment elevation myocardial infarction (STEMI) patients are more likely to achieve lipid-lowering treatment goals. Medicine (United States), 2018, 97, e12225.	0.4	6
257	Timing of high intensity statin for acute coronary syndrome: how earlier initiation makes better?. Journal of Thoracic Disease, 2018, 10, S2149-S2152.	0.6	2
258	The â€œcholesterol paradoxâ€•among inpatients â€“ retrospective analysis of medical documentation. Archives of Medical Sciences Atherosclerotic Diseases, 2018, 3, 46-57.	0.5	13
259	Convincing evidence supports reducing saturated fat to decrease cardiovascular disease risk. BMJ Nutrition, Prevention and Health, 2018, 1, 23-26.	1.9	25
260	Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 2018, 8, e021508.	0.8	14
261	Less Medication Use in Inpatients With Severe Mental Illness Receiving a Multidisciplinary Lifestyle Enhancing Treatment. The MULTI Study III. Frontiers in Psychiatry, 2018, 9, 707.	1.3	11
262	Effects of polymorphisms in APOB, APOE, HSD11Î²1, PLIN4, and ADIPOQ genes on lipid profile and anthropometric variables related to obesity in children and adolescents. Genetics and Molecular Biology, 2018, 41, 735-741.	0.6	5
263	The effect of brief versus individually tailored dietary advice on change in diet, lipids and blood pressure in patients with inflammatory joint disease. Food and Nutrition Research, 2018, 62, .	1.2	4
264	Dyslipidemia in Adolescents Seen in a University Hospital in the city of Rio de Janeiro/Brazil: Prevalence and Association. Arquivos Brasileiros De Cardiologia, 2018, 112, 147-151.	0.3	7
265	Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients. Therapeutics and Clinical Risk Management, 2018, Volume 14, 2425-2435.	0.9	2
266	Degenerative Aortic Stenosis, Dyslipidemia and Possibilities of Medical Treatment. Medicina (Lithuania), 2018, 54, 24.	0.8	13
267	OBSOLETE: Biomarkers in Ischemic Heart Disease. , 2018, , .		0
268	Needs survey on the priority given to periodical medical examination items among occupational physicians in Japan. Journal of Occupational Health, 2018, 60, 502-514.	1.0	2
270	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. Korean Circulation Journal, 2018, 48, 1097.	0.7	15
271	Pragmatic trial of multifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack â€“study protocol. BMC Neurology, 2018, 18, 187.	0.8	20
272	Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences. JAMA Cardiology, 2018, 3, 1192.	3.0	48
273	Documento de recomendaciones de la SEA 2018. El estilo de vida en la prevenciÃ³n cardiovascular. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2018, 30, 280-310.	0.4	20
274	Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. Lipids in Health and Disease, 2018, 17, 265.	1.2	18

#	Article	IF	Citations
275	Coronary artery stenosis and associations with indicators of anthropometric and diet in patients undergoing coronary angiography. Journal of Diabetes and Metabolic Disorders, 2018, 17, 203-210.	0.8	6
276	Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis. Current Rheumatology Reports, 2018, 20, 81.	2.1	31
277	Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA. Scientific Reports, 2018, 8, 16174.	1.6	23
278	Document of recommendations of the SEA 2018. Lifestyle in cardiovascular prevention. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2018, 30, 280-310.	0.1	5
279	Different age-independent effects of nutraceutical combinations on endothelium-mediated coronary flow reserve. Immunity and Ageing, 2018, 15, 30.	1.8	5
280	Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis. PLoS ONE, 2018, 13, e0207889.	1.1	9
281	Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjects. Translational and Clinical Pharmacology, 2018, 26, 16.	0.3	5
282	Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk. Patient Preference and Adherence, 2019, Volume 13, 9-19.	0.8	15
283	El concepto de hipertrigliceridemia severa y sus implicaciones para la prÃ¡ctica clÃnica. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2018, 30, 193-196.	0.4	4
284	Statins and risk of cataracts: A systematic review and metaâ€analysis of observational studies. Cardiovascular Therapeutics, 2018, 36, e12480.	1.1	14
285	The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases. International Journal of Molecular Sciences, 2018, 19, 4058.	1.8	46
286	Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy. Clinical Medicine Insights: Cardiology, 2018, 12, 117954681881516.	0.6	3
287	Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters. Nutrients, 2018, 10, 1842.	1.7	8
288	Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. JAMA Network Open, 2018, 1, e185554.	2.8	67
289	Autoimmune activation as a determinant of atrial fibrillation among Turks. Medicine (United States), 2018, 97, e11779.	0.4	6
290	Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register. BMC Health Services Research, 2018, 18, 900.	0.9	10
291	Statin-induced myopathy: a case report. European Heart Journal - Case Reports, 2018, 2, yty130.	0.3	2
292	A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 57 Td		

#	Article	IF	Citations
293	Alirocumab dosing patterns during 40Âmonths of open-label treatment in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 1463-1470.	0.6	2
294	Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Atherosclerosis, 2018, 277, 355-361.	0.4	21
295	Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis, 2018, 277, 483-492.	0.4	128
296	Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review. Atherosclerosis, 2018, 277, 383-391.	0.4	73
297	Medicationâ€based versus targetâ€based lipid management. Journal of Diabetes, 2018, 10, 789-792.	0.8	1
298	Effect of simvastatin on expression of VEGF and TGF-Î²1 in atherosclerotic animal model of typeï¿½2 diabetes mellitus. Experimental and Therapeutic Medicine, 2018, 16, 2889-2894.	0.8	0
299	The concept of severe hypertriglyceridaemia and its implications for clinical practice. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2018, 30, 193-196.	0.1	0
301	Postprandial Lipid Concentrations and Daytime Biological Variation of Lipids in a Healthy Chinese Population. Annals of Laboratory Medicine, 2018, 38, 431-439.	1.2	11
302	Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction. PLoS ONE, 2018, 13, e0205006.	1.1	7
303	Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population. International Journal of Molecular Sciences, 2018, 19, 49.	1.8	9
304	LDL-Cholesterol Lowering of Plant Sterols and Stanolsâ€"Which Factors Influence Their Efficacy?. Nutrients, 2018, 10, 1262.	1.7	66
305	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. Cmaj, 2018, 190, E1192-E1206.	0.9	39
306	Investigating potential mediator between statin and coronary artery calcification. PLoS ONE, 2018, 13, e0203702.	1.1	9
307	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.4	48
308	Single and combined effects of peripheral artery disease and of type 2 diabetes mellitus on the risk of cardiovascular events: A prospective cohort study. Atherosclerosis, 2018, 279, 32-37.	0.4	12
309	Management of High and Very High-Risk Subjects with Familial Hypercholesterolemia: Results from an Observational Study in Bulgaria. Folia Medica, 2018, 60, 389-396.	0.2	4
310	A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK®) lowering cardiovascular disease risk. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 601-609.	0.7	3
311	Mountain Ultramarathon Induces Early Increases of Muscle Damage, Inflammation, and Risk for Acute Renal Injury. Frontiers in Physiology, 2018, 9, 1368.	1.3	23

#	Article	IF	Citations
312	Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs in Context, 2018, 7, 212534.	1.0	44
313	Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 727-749.	4.1	153
314	Cardiovascular risk assessment of dyslipidemic middle-aged adults without overt cardiovascular disease over the period of 2009â€“2016 in Lithuania. Lipids in Health and Disease, 2018, 17, 233.	1.2	4
315	Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. Current Diabetes Reports, 2018, 18, 138.	1.7	4
316	COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 683-697.	1.1	19
317	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. Journal of Atherosclerosis and Thrombosis, 2018, 25, 846-984.	0.9	541
318	Association of time of obesity onset with comorbidities in treatmentâ€seeking men and women with severe obesity. Obesity Science and Practice, 2018, 4, 427-436.	1.0	8
319	Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China. Lipids in Health and Disease, 2018, 17, 241.	1.2	57
320	Do acute coronary events affect lipid management and cholesterol goal attainment in Germany?. Wiener Klinische Wochenschrift, 2018, 130, 707-715.	1.0	4
321	Primary prevention with statins for older adults. BMJ: British Medical Journal, 2018, 362, k3695.	2.4	6
322	Clinical management of heterozygous familial hypercholesterolemia in a Polish outpatient metabolic clinic: a retrospective observational study. Archives of Medical Science, 2018, 14, 962-970.	0.4	4
323	Comparison of the application of treatment Panel III and American College of Cardiology/American heart Association guidelines for blood cholesterol treatment in Saudi Arabia. Journal of the Saudi Heart Association, 2018, 30, 349-355.	0.2	2
324	Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 355-359.	1.0	1
325	Early life predictors of midlife allostatic load: A prospective cohort study. PLoS ONE, 2018, 13, e0202395.	1.1	14
326	Should Measures of High-Density Lipoprotein Function Be Added to the Low-Density Lipoprotein Cholesterol Target Level-Based Guidelines for Prevention of Atherosclerotic Disease?. Circulation Journal, 2018, 82, 1251-1252.	0.7	0
327	Genetic and Environmental Dispositions for Cardiovascular Variability: A Pilot Study. Journal of Clinical Medicine, 2018, 7, 232.	1.0	3
328	Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. European Heart Journal, 2018, 39, 3641-3653.	1.0	69
329	Fenofibrate and Dyslipidemia: Still a Place in Therapy?. Drugs, 2018, 78, 1289-1296.	4.9	11

#	Article	IF	Citations
330	Epidemiology and Etiology of Acute Pancreatitis in Urban and Suburban Areas in Shanghai: A Retrospective Study. Gastroenterology Research and Practice, 2018, 2018, 1-8.	0.7	23
331	Statin Use and Adverse Effects Among Adults >75ÂYears of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. Journal of the American Heart Association, 2018, 7, .	1.6	49
332	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clinical Chemistry, 2018, 64, 1006-1033.	1.5	189
333	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. GastroenterologÃa Y HepatologÃa (English Edition), 2018, 41, 328-349.	0.0	7
334	Are PCSK9 Inhibitors Cost Effective?. Pharmacoeconomics, 2018, 36, 1031-1041.	1.7	24
335	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. Diabetes Therapy, 2018, 9, 1317-1334.	1.2	21
336	Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives. BMJ Open, 2018, 8, e021309.	0.8	12
337	Standardization of laboratory and lipid profile evaluation: A call for action with a special focus in 2016 ESC/EAS dyslipidaemia guidelines â€“ Full report. Atherosclerosis Supplements, 2018, 31, e1-e12.	1.2	20
338	Plant sterols lower LDL-cholesterol and triglycerides in dyslipidemic individuals with or at risk of developing type 2 diabetes; a randomized, double-blind, placebo-controlled study. Nutrition and Diabetes, 2018, 8, 30.	1.5	28
339	Prognosis and lipid profile improvement by a specialized outpatient clinic for acute coronary syndrome patients. Atherosclerosis, 2018, 275, 28-34.	0.4	9
340	Statin Utilization Patterns and Outcomes for Patients with Acute Coronary Syndrome During and Following Inpatient Admissions. Cardiovascular Drugs and Therapy, 2018, 32, 273-280.	1.3	10
341	Treatment target re-classification of subjects comparing estimation of low-density lipoprotein cholesterol by the Friedewald equation and direct measurement of LDL-cholesterol. Upsala Journal of Medical Sciences, 2018, 123, 94-99.	0.4	6
342	Alirocumab as add-on therapy to statins: current evidence and clinical potential. Therapeutic Advances in Cardiovascular Disease, 2018, 12, 191-202.	1.0	4
343	Biomarkers in Ischemic Heart Disease. , 2018, , 303-314.		0
344	Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	6.7	20
345	Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials?. Indian Heart Journal, 2018, 70, 331-334.	0.2	0
346	Beneficial effect of statins in patients receiving chronic hemodialysis following percutaneous coronary intervention: A nationwide retrospective cohort study. Scientific Reports, 2018, 8, 9692.	1.6	11
347	Endocytosis of lipoproteins. Atherosclerosis, 2018, 275, 273-295.	0.4	65

#	Article	IF	Citations
348	PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. Journal of the American Heart Association, 2018, 7, .	1.6	54
349	The Role of Nutraceuticals in StatinÂIntolerant Patients. Journal of the American College of Cardiology, 2018, 72, 96-118.	1.2	216
350	Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial. Clinical Cardiology, 2018, 41, 1117-1122.	0.7	11
351	Drug Adherence in Hypertension and Cardiovascular Protection. Updates in Hypertension and Cardiovascular Protection, 2018, , .	0.1	5
352	Coronary Calcium Score vs. Computed Tomography Angiography as Tools to Stratify Cardiovascular Risk. Current Cardiovascular Risk Reports, 2018, 12, 1.	0.8	1
353	Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East. International Journal of General Medicine, 2018, Volume 11, 313-322.	0.8	33
354	LDL Cholesterol Rises With BMI Only in Lean Individuals: Cross-sectional U.S. and Spanish Representative Data. Diabetes Care, 2018, 41, 2195-2201.	4.3	28
356	Exercise and weight loss effects on cardiovascular risk factors in overweight men. Journal of Applied Physiology, 2018, 125, 901-908.	1.2	18
357	Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine?. Anticancer Research, 2018, 38, 4393-4402.	0.5	16
358	Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World Journal of Diabetes, 2018, 9, 1-24.	1.3	145
359	Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. Journal of Stroke, 2018, 20, 145-166.	1.4	39
360	Hypercholesterolaemia â€“ practical information for non-specialists. Archives of Medical Science, 2018, 1, 1-21.	0.4	39
361	Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. Frontiers in Pharmacology, 2018, 9, 707.	1.6	31
362	A Pathways Approach to the Metabolic Syndrome. , 2018, , 181-193.		0
363	Effect of Pioglitazone in Combination with Moderate Dose Statin on Atherosclerotic Inflammation: Randomized Controlled Clinical Trial Using Serial FDG-PET/CT. Korean Circulation Journal, 2018, 48, 591.	0.7	11
364	Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study. European Journal of Preventive Cardiology, 2018, 25, 1887-1898.	0.8	21
365	Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients â€“ A consensus document. Indian Heart Journal, 2018, 70, 736-744.	0.2	4
366	Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis. Endocrinology and Metabolism, 2018, 33, 219.	1.3	18

#	Article	IF	Citations
367	Apolipoprotein B/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients. Lipids in Health and Disease, 2018, 17, 117.	1.2	23
368	Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond. Frontiers in Cardiovascular Medicine, 2018, 5, 62.	1.1	72
369	Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. Diseases (Basel, Switzerland), 2018, 6, 44.	1.0	3
370	PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. Expert Review of Cardiovascular Therapy, 2018, 16, 567-578.	0.6	11
371	The Evolving Future of PCSK9 Inhibitors. Journal of the American College of Cardiology, 2018, 72, 314-329.	1.2	162
372	Awareness of Pleiotropic and Cardioprotective Effect of Statins in Patients with Coronary Artery Disease. BioMed Research International, 2018, 2018, 1-7.	0.9	6
373	Effectiveness and Safety of Dietetic Supplementation of a New Nutraceutical on Lipid Profile and Serum Inflammation Biomarkers in Hypercholesterolemic Patients. Molecules, 2018, 23, 1168.	1.7	22
374	Habitual Flavonoid Intake from Fruit and Vegetables during Adolescence and Serum Lipid Levels in Early Adulthood: A Prospective Analysis. Nutrients, 2018, 10, 488.	1.7	15
375	Clozapine Patients at the Interface between Primary and Secondary Care. Pharmacy (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 422 T	0.6	6
376	Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank. European Heart Journal, 2018, 39, 3253-3261.	1.0	42
377	Associations between circulating full-length angiopoietin-like protein 8 levels and severity of coronary artery disease in Chinese non-diabetic patients: a caseâ€“control study. Cardiovascular Diabetology, 2018, 17, 92.	2.7	18
378	Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. Journal of the American Board of Family Medicine, 2018, 31, 628-634.	0.8	11
379	Clinical and Economic Analysis of Lipid Goal Attainments in Chinese Patients with Acute Coronary Syndrome Who Received Post-Percutaneous Coronary Intervention. Journal of Atherosclerosis and Thrombosis, 2018, 25, 1255-1273.	0.9	5
380	Cardiovascular Risk Factors Accelerate Kidney Function Decline in Postâ^'Myocardial InfarctionÂPatients: The Alpha Omega Cohort Study. Kidney International Reports, 2018, 3, 879-888.	0.4	10
381	Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. European Heart Journal, 2018, 39, 2562-2573.	1.0	126
382	Lipoprotein(a): the perpetual supporting actor. European Heart Journal, 2018, 39, 2597-2599.	1.0	11
383	Association between circulating full-length angiopoietin-like protein 8 and non-high-density lipoprotein cholesterol levels in Chinese non-diabetic individuals: a cross-sectional study. Lipids in Health and Disease, 2018, 17, 161.	1.2	7
384	High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD). Circulation, 2018, 137, 1997-2009.	1.6	174

#	Article	IF	Citations
385	Improved insulin sensitivity and lower postprandial triglyceride concentrations after cold-pressed turnip rapeseed oil compared to cream in patients with metabolic syndrome. Diabetology and Metabolic Syndrome, 2018, 10, 38.	1.2	2
386	Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?. Current Cardiology Reports, 2018, 20, 88.	1.3	18
387	Comparison of various lipid parameters in association of target organ damage: a cohort study. Lipids in Health and Disease, 2018, 17, 199.	1.2	16
388	Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study. Scientific Reports, 2018, 8, 11925.	1.6	8
389	Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. Diseases (Basel, Switzerland), 2018, 6, 22.	1.0	10
390	Strategies to achieve low-density lipoprotein cholesterol targets in high-risk patients. Current Medical Research and Opinion, 2018, 34, 1713-1715.	0.9	0
391	Population distribution of traditional and the emerging cardiovascular risk factors carotid plaque and IMT: the REFINE-Reykjavik study with comparison with the TromsÃ¸ study. BMJ Open, 2018, 8, e019385.	0.8	9
392	Porphyromonas gingivalis vesicles reduce MDA-LDL levels and aortic wall thickness in high fat diet induced atherosclerosis rats. Artery Research, 2018, 23, 20.	0.3	2
393	Effects of boron-containing compounds on cardiovascular disease risk factors â€“ A review. Journal of Trace Elements in Medicine and Biology, 2018, 50, 47-56.	1.5	52
394	Statinâ€associated myopathy. Assessment of frequency based on data of all statutory health insurance funds in Germany. Pharmacology Research and Perspectives, 2018, 6, e00404.	1.1	12
395	Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovascular Research, 2018, 114, 1073-1081.	1.8	49
396	Inverse Association Between Serum Nonâ€“Highâ€Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis. Journal of the American Heart Association, 2018, 7, .	1.6	20
397	Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation. JAMA Cardiology, 2018, 3, 749.	3.0	105
398	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an â€œFCS scoreâ€. Atherosclerosis, 2018, 275, 265-272.	0.4	131
399	Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLoS Medicine, 2018, 15, e1002538.	3.9	67
400	Impact on Dyslipidemia After Laparoscopic Sleeve Gastrectomy. Obesity Surgery, 2018, 28, 3111-3115.	1.1	10
401	Standardization of laboratory lipid profile assessment: A call for action with a special focus on the 2016 ESC/EAS dyslipidemia guidelines â€“ Executive summary. Revista Portuguesa De Cardiologia (English) Tj ETQq1 1 0.2 0 rgBT /Overlock		
402	Effect of various Danshen injections on patients with coronary heart disease after percutaneous coronary intervention. Medicine (United States), 2018, 97, e11062.	0.4	6

#	Article	IF	Citations
403	Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now. Canadian Journal of Cardiology, 2019, 35, 590-597.	0.8	4
404	Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan. Journal of Atherosclerosis and Thrombosis, 2019, 26, 282-293.	0.9	9
405	Hypercholesterolemia. , 2019, , 320-326.		7
406	Cardiometabolic risk factors differ among adolescents with obesity in three European countries - a cross-sectional study. Acta Paediatrica, International Journal of Paediatrics, 2019, 108, 493-501.	0.7	2
407	A low-fat spread with added plant sterols and fish omega-3 fatty acids lowers serum triglyceride and LDL-cholesterol concentrations in individuals with modest hypercholesterolaemia and hypertriglyceridaemia. European Journal of Nutrition, 2019, 58, 1615-1624.	1.8	23
408	Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD. Kidney International Reports, 2019, 4, 1546-1554.	0.4	15
409	The effects of Qigong exercises on blood lipid profiles of middle-aged and elderly individuals: A systematic review and network meta-analysis. European Journal of Integrative Medicine, 2019, 30, 100950.	0.8	2
410	Outcomes of nurse-led clinic for patients treated with percutaneous coronary intervention: A retrospective analysis. Applied Nursing Research, 2019, 49, 19-22.	1.0	3
411	Pregnancy Complication History in 10-Year Cardiovascular Disease Risk Prediction: a Review of Recent Evidence. Current Epidemiology Reports, 2019, 6, 321-328.	1.1	8
412	The Bioequivalence and Effect of Food on the Pharmacokinetics of a Fixedâ€Dose Combination Tablet Containing Rosuvastatin and Ezetimibe in Healthy Japanese Subjects. Clinical and Translational Science, 2019, 12, 704-712.	1.5	4
413	Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3939-3985.	1.8	42
414	Lp(a): Addressing a Target for Cardiovascular Disease Prevention. Current Cardiology Reports, 2019, 21, 102.	1.3	14
415	Effect of statin treatment on circulating malondialdehyde concentrations: a systematic review and meta-analysis. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986271.	1.1	8
416	Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. Current Cardiology Reports, 2019, 21, 110.	1.3	24
417	Substituting polyunsaturated fat for saturated fat: A health impact assessment of a fat tax in seven European countries. PLoS ONE, 2019, 14, e0218464.	1.1	3
418	Alirocumab in Patients With Polyvascular Disease and Recent Acute CoronaryÂSyndrome. Journal of the American College of Cardiology, 2019, 74, 1167-1176.	1.2	154
419	Primary Mixed Dyslipidemias. , 2019, , 314-319.		1
420	The cost-effectiveness of omega-3 polyunsaturated fatty acids â€“ The Australian healthcare perspective. European Journal of Internal Medicine, 2019, 67, 70-76.	1.0	14

#	Article	IF	Citations
421	Prognostic implications of statin intolerance in stable coronary artery disease patients with different levels of high-sensitive troponin. BMC Cardiovascular Disorders, 2019, 19, 168.	0.7	5
422	Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 263-272.	1.0	7
423	Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition. Current Diabetes Reports, 2019, 19, 61.	1.7	44
424	N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. European Heart Journal, 2019, 40, 2785-2796.	1.0	159
425	Plasma Phospholipid Fatty Acids and Coronary Heart Disease Risk: A Matched Case-Control Study within the Womenâ€™s Health Initiative Observational Study. Nutrients, 2019, 11, 1672.	1.7	18
426	Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients. Journal of Clinical Medicine, 2019, 8, 1080.	1.0	33
427	Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. Current Atherosclerosis Reports, 2019, 21, 41.	2.0	53
428	Correlations between Traditional and Nontraditional Indicators of Adiposity, Inflammation, and Monocyte Subtypes in Patients with Stable Coronary Artery Disease. Journal of Obesity, 2019, 2019, 1-11.	1.1	9
429	PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk. Current Atherosclerosis Reports, 2019, 21, 40.	2.0	6
430	Statin use and high-dose statin use after ischemic stroke in the UK: a retrospective cohort study . Clinical Epidemiology, 2019, Volume 11, 495-508.	1.5	13
431	Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. European Heart Journal, 2019, 40, 3516-3525.	1.0	97
432	Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis. Journal of Clinical Lipidology, 2019, 13, 538-549.	0.6	16
433	Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 199-207.	1.0	10
434	Goals of non-high density lipoprotein cholesterol need to be adjusted in Chinese acute coronary syndrome patients: Findings from the CCC-ACS project. Clinica Chimica Acta, 2019, 496, 48-54.	0.5	10
435	Selective screening for familial hypercholesterolemia in Austrian children - first year results. BMC Pediatrics, 2019, 19, 208.	0.7	9
436	Negative Risk Markers for Cardiovascular Events in the Elderly. Journal of the American College of Cardiology, 2019, 74, 1-11.	1.2	71
437	Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage. Neurology, 2019, 93, e445-e457.	1.5	119
438	EstÃ¡ndares SEA 2019 para el control global del riesgo cardiovascular. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 1-43.	0.4	8

#	Article	IF	Citations
439	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5253-5262.	1.8	4
441	Exploration dâ€™une anomalie lipidique : quoi de neuf en 2019 ?. Option/Bio, 2019, 30, 25-27.	0.0	0
442	Gene Editing: Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein (Small 38/2019). Small, 2019, 15, 1970205.	5.2	7
443	Treatment with Statins in Elderly Patients. Medicina (Lithuania), 2019, 55, 721.	0.8	47
445	2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e000057.	0.9	46
446	Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients . Therapeutics and Clinical Risk Management, 2019, Volume 15, 1209-1216.	0.9	1
447	Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Scientific Reports, 2019, 9, 16632.	1.6	35
448	Associations between Dietary Pulses Alone or with Other Legumes and Cardiometabolic Disease Outcomes: An Umbrella Review and Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. Advances in Nutrition, 2019, 10, S308-S319.	2.9	74
449	Effect of coadministration of enriched Korean Red Ginseng (Panax ginseng) and American ginseng (Panax quinquefolius L) on cardiometabolic outcomes in type-2 diabetes: A randomized controlled trial. Journal of Ginseng Research, 2021, 45, 546-554.	3.0	12
450	Update of therapeutic planning tables oriented towards obtaining therapeutic objectives. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2019, 31, 271-277.	0.1	3
451	Au-delÃ du risque cardiovasculaire : le rÃ1e des lipoprotÃ©ines contenant lâ€™apoB athÃ©rogÃ¨nes dans lâ€™Ã©tiologie du diabÃ¨te de type 2. Medecine Des Maladies Metaboliques, 2019, 13, 129-139.	0.1	3
453	A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease. British Journal of Clinical Pharmacology, 2019, 85, 2878-2885.	1.1	8
454	2018 Guidelines for the Management of Dyslipidemia in Korea. Journal of Lipid and Atherosclerosis, 2019, 8, 78.	1.1	100
455	Bioactive compounds from herbal medicines to manage dyslipidemia. Biomedicine and Pharmacotherapy, 2019, 118, 109338.	2.5	49
456	Nutritional Challenges in Metabolic Syndrome. Journal of Clinical Medicine, 2019, 8, 1301.	1.0	54
457	Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?. Archives of Medical Sciences Atherosclerotic Diseases, 2019, 4, 144-150.	0.5	5
458	Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. International Journal of Environmental Research and Public Health, 2019, 16, 3104.	1.2	135
459	Therapeutic effects of statins on chromosomal DNA damage of dyslipidemic patients. Experimental Biology and Medicine, 2019, 244, 1089-1095.	1.1	8

#	Article	IF	Citations
460	Cohort profile: role of lipoproteins in cardiovascular diseaseâ€"the LipidCardio study. BMJ Open, 2019, 9, e030097.	0.8	14
461	Anxiety and depression relationship with coronary slow flow. PLoS ONE, 2019, 14, e0221918.	1.1	8
463	CODAP: um consenso multidisciplinar sobre a definiÃ§Ã£o, diagnÃ³stico e tratamento da dislipidemia aterogÃ©nica em Portugal. Revista Portuguesa De Cardiologia, 2019, 38, 531-542.	0.2	4
464	Lipid findings from the Diabetes Education to Lower Insulin, Sugars, and Hunger (DELISH) Study. Nutrition and Metabolism, 2019, 16, 58.	1.3	7
465	Renal impact of highâ€'loadingâ€'dose statin preâ€'cardiac catheterization in patients with chronic kidney disease and longâ€'term statin use. Experimental and Therapeutic Medicine, 2019, 18, 1609-1618.	0.8	1
466	The cardiovascular phenotype of adult patients with phenylketonuria. Orphanet Journal of Rare Diseases, 2019, 14, 213.	1.2	33
467	Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care. Atherosclerosis, 2019, 290, 1-8.	0.4	51
468	Hormonal, metabolic and inflammatory circulating biomarker profiles in obese and non-obese Brazilian middle-aged women. PLoS ONE, 2019, 14, e0222239.	1.1	2
469	Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study. Journal of Lipids, 2019, 2019, 1-8.	1.9	11
470	Hydroethanolic plant extracts from Cameroon positively modulate enzymes relevant to carbohydrate/lipid digestion and cardio-metabolic diseases. Food and Function, 2019, 10, 6533-6542.	2.1	13
471	Lipid management for coronary heart disease patients: an appraisal of updated international guidelines applying Appraisal of Guidelines for Research and Evaluation IIâ€"clinical practice guideline appraisal for lipid management in coronary heart disease. Journal of Thoracic Disease, 2019, 11, 3534-3546.	0.6	8
472	Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ: British Medical Journal, 2019, 366, l5125.	2.4	58
473	Hemodynamic differences among hypertensive patients with and without heart failure using impedance cardiography. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471987651.	1.0	10
474	Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2248-2260.	1.1	60
475	Statin-induced muscular side effects at rest and exercise â€" An anatomical mapping. Atherosclerosis Supplements, 2019, 40, 73-78.	1.2	9
476	Statins in Females. Indian Journal of Cardiovascular Disease in Women WINCARS, 2019, 04, 099-106.	0.1	0
477	Aortic intima-media thickness can be used to determine target organ damage in adult patients with coronary artery disease risk factors. Archives of Medical Sciences Atherosclerotic Diseases, 2019, 4, 183-190.	0.5	8
478	Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989â€"2017. Atherosclerosis, 2019, 290, 44-51.	0.4	25

#	Article	IF	Citations
479	Socioeconomic and geographic variations in the prevalence, awareness, treatment and control of dyslipidemia in middle-aged and older Chinese. Atherosclerosis, 2019, 282, 57-66.	0.4	32
481	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, The, 2019, 393, 407-415.	6.3	512
482	Cholesterol-Lowering Agents. Circulation Research, 2019, 124, 364-385.	2.0	45
483	Effect of Statin Therapy on Arterial Wall Inflammation Based on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis of Interventional Studies. Journal of Clinical Medicine, 2019, 8, 118.	1.0	48
484	LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study. Atherosclerosis, 2019, 282, 37-44.	0.4	38
485	Association Between Serum Lipid Profile and Obstructive Respiratory Events During REM and Non-REM Sleep. Lung, 2019, 197, 443-450.	1.4	20
486	Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination. American Journal of Cardiovascular Drugs, 2019, 19, 237-247.	1.0	10
487	A Boost in Mitochondrial Activity Underpins the Cholesterol-Lowering Effect of Annurca Apple Polyphenols on Hepatic Cells. Nutrients, 2019, 11, 163.	1.7	24
488	Targeting RNA to lower triglycerides: long strides from short molecules. European Heart Journal, 2019, 40, 2797-2800.	1.0	10
489	Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis. Frontiers in Pharmacology, 2019, 10, 547.	1.6	14
490	Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort. Vascular Pharmacology, 2019, 120, 106566.	1.0	15
491	Prevalence and Predictors of Statin Treatment Among Patients With Chronic Heart Failure at a Tertiary-Care Center in Thailand. Clinical Medicine Insights: Cardiology, 2019, 13, 117954681985565.	0.6	4
492	New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease. Current Cardiology Reports, 2019, 21, 69.	1.3	13
493	Recent advances in novel therapies for lipid disorders. Human Molecular Genetics, 2019, 28, R49-R54.	1.4	15
494	Relationship Between Dynamic Changes in Body Weight and Blood Pressure: The ESTEBAN Survey. American Journal of Hypertension, 2019, 32, 1003-1012.	1.0	7
495	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. Atherosclerosis, 2019, 287, 89-92.	0.4	29
496	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	2.7	104
497	Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia. Lipids in Health and Disease, 2019, 18, 129.	1.2	18

#	Article	IF	Citations
498	Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. Lipids in Health and Disease, 2019, 18, 134.	1.2	40
499	Effect of quantitative and qualitative diet prescription on children behavior after diagnosis of heterozygous familial hypercholesterolemia. International Journal of Cardiology, 2019, 293, 193-196.	0.8	17
500	High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus . Vascular Health and Risk Management, 2019, Volume 15, 149-157.	1.0	57
501	Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias. Lipids in Health and Disease, 2019, 18, 119.	1.2	6
502	Biological variation data for lipid cardiovascular risk assessment biomarkers. A systematic review applying the biological variation data critical appraisal checklist (BIVAC). Clinica Chimica Acta, 2019, 495, 467-475.	0.5	27
503	Estimation of cardiovascular risk based on total cholesterol versus total cholesterol/high-density lipoprotein within different ethnic groups: The HELIUS study. European Journal of Preventive Cardiology, 2019, 26, 1888-1896.	0.8	3
504	Lipoprotein (a) and 10-year Cardiovascular Disease Incidence in Apparently Healthy Individuals: A Sex-based Sensitivity Analysis from ATTICA Cohort Study. Angiology, 2019, 70, 819-829.	0.8	19
505	Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study. Advances in Therapy, 2019, 36, 2010-2020.	1.3	13
506	Effect of Nutrient and Micronutrient Intake on Chylomicron Production and Postprandial Lipemia. Nutrients, 2019, 11, 1299.	1.7	48
507	A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives. International Urology and Nephrology, 2019, 51, 1173-1189.	0.6	10
508	Functional analysis of new variants at the Low Density Lipoprotein Receptor associated with familial hypercholesterolemia. Human Mutation, 2019, 40, 1181-1190.	1.1	10
510	Effects of a Novel Nutraceutical Combination (Aquilea ColesterolÂ®) on the Lipid Profile and Inflammatory Biomarkers: A Randomized Control Trial. Nutrients, 2019, 11, 949.	1.7	8
511	Statins for primary prevention of cardiovascular disease: modelling guidelines and patient preferences based on an Irish cohort. British Journal of General Practice, 2019, 69, e373-e380.	0.7	10
512	Coronary plaque characteristics and epicardial fat tissue in long term survivors of type 1 diabetes identified by coronary computed tomography angiography. Cardiovascular Diabetology, 2019, 18, 58.	2.7	18
513	Elevated triglycerides rather than other lipid parameters are associated with increased urinary albumin to creatinine ratio in the general population of China: a report from the REACTION study. Cardiovascular Diabetology, 2019, 18, 57.	2.7	13
514	Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study. Chemical and Pharmaceutical Bulletin, 2019, 67, 419-425.	0.6	4
515	Lysosomal Acid Lipase as a Molecular Target of the Very Low Carbohydrate Ketogenic Diet in Morbidly Obese Patients: The Potential Effects on Liver Steatosis and Cardiovascular Risk Factors. Journal of Clinical Medicine, 2019, 8, 621.	1.0	24
516	Statins and nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 1787-1787.	1.9	3

#	Article	IF	Citations
517	Statin use and delayed onset of Huntington's disease. Movement Disorders, 2019, 34, 762-763.	2.2	2
518	Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. Journal of Clinical Lipidology, 2019, 13, 525-537.	0.6	45
519	Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes. Cardiology Research and Practice, 2019, 2019, 1-7.	0.5	6
520	Comparison of non-fasting LDL-C levels calculated by Friedewald formula with those directly measured in Chinese patients with coronary heart disease after a daily breakfast. Clinica Chimica Acta, 2019, 495, 399-405.	0.5	17
521	Guideline Alignment in Related Areas. Canadian Journal of Cardiology, 2019, 35, 606-610.	0.8	1
522	The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of â€œreal worldâ€•practice in people with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 17-27.	2.2	8
523	Effects of Silymarin on the In Vivo Pharmacokinetics of Simvastatin and Its Active Metabolite in Rats. Molecules, 2019, 24, 1666.	1.7	4
524	The effects of secondary prevention after coronary revascularization in Taiwan. PLoS ONE, 2019, 14, e0215811.	1.1	4
525	Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases. Nature Communications, 2019, 10, 1981.	5.8	49
526	Diabetogenic Action of Statins: Mechanisms. Current Atherosclerosis Reports, 2019, 21, 23.	2.0	43
527	Diosgenin regulates cholesterol metabolism in hypercholesterolemic rats by inhibiting NPC1L1 and enhancing ABCG5 and ABCG8. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 1124-1133.	1.2	34
528	Combining Plant Sterols With Walking Lowers Postprandial Triacylglycerol More Than Walking Only in Chinese Men With Elevated Body Mass Index. International Journal of Sport Nutrition and Exercise Metabolism, 2019, 29, 576-582.	1.0	4
529	Is There a Need to Revise Goals in the Management of Dyslipidemias?. Current Cardiology Reports, 2019, 21, 51.	1.3	6
530	Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs, 2019, 79, 751-766.	4.9	86
531	Perils of Observational Data Analyses. Journal of the American Heart Association, 2019, 8, e012490.	1.6	1
532	Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review. BMC Pediatrics, 2019, 19, 106.	0.7	10
533	Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. BMJ Open, 2019, 9, e023085.	0.8	51
534	Chokeberry Juice Containing Polyphenols Does Not Affect Cholesterol or Blood Pressure but Modifies the Composition of Plasma Phospholipids Fatty Acids in Individuals at Cardiovascular Risk. Nutrients, 2019, 11, 850.	1.7	31

#	Article	IF	Citations
535	PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab. Journal of Clinical Lipidology, 2019, 13, 443-454.	0.6	2
536	Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. Frontiers in Psychiatry, 2019, 10, 103.	1.3	77
537	Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis. Cardiovascular Diabetology, 2019, 18, 38.	2.7	45
538	A Randomized Clinical Efficacy Trial of Red Yeast Rice (Monascus pilosus) Against Hyperlipidemia. The American Journal of Chinese Medicine, 2019, 47, 323-335.	1.5	24
539	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 140, e596-e646.	1.6	1,789
540	Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Annals of Clinical Biochemistry, 2019, 56, 338-356.	0.8	27
541	Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?. Current Atherosclerosis Reports, 2019, 21, 14.	2.0	15
542	Laboratory medicine: health evaluation in elite athletes. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1450-1473.	1.4	25
543	Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography. Atherosclerosis, 2019, 284, 24-30.	0.4	37
544	Effect of Statin Therapy and Long-Term Mortality Following Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2019, 123, 1978-1982.	0.7	8
545	A review of gene- and cell-based therapies for familial hypercholesterolemia. Pharmacological Research, 2019, 143, 119-132.	3.1	24
546	Associations of non-high-density lipoprotein cholesterol, triglycerides and the total cholesterol/HDL-c ratio with arterial stiffness independent of low-density lipoprotein cholesterol in a Chinese population. Hypertension Research, 2019, 42, 1223-1230.	1.5	38
547	Trials in â€œTrueâ€•Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk. Clinical Pharmacology and Therapeutics, 2019, 106, 960-967.	2.3	2
548	To test, or not to test: that is the question for the future of lipoprotein(a). Expert Review of Cardiovascular Therapy, 2019, 17, 241-250.	0.6	4
549	Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 315-322.	1.0	14
550	Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Preâ€specified analysis of the Chinese population from the BERSON clinical trial. Diabetes, Obesity and Metabolism, 2019, 21, 1464-1473.	2.2	21
551	The benefit of secondary prevention with oat fiber in reducing future cardiovascular event among CAD patients after coronary intervention. Scientific Reports, 2019, 9, 3091.	1.6	11
552	The characteristics of two LDL-cholesterol level reduction treatment strategies, â€œtreat-to-targetâ€• and â€œpercent reductionâ€• an observational study without intervention. BMC Cardiovascular Disorders, 2019, 19, 57.	0.7	1

#	Article	IF	Citations
553	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocrine Reviews, 2019, 40, 537-557.	8.9	262
554	Effectiveness of a Novel Nutraceutical Compound Containing Red Yeast Rice, Polymethoxyflavones and Antioxidants in the Modulation of Cholesterol Levels in Subjects With Hypercholesterolemia and Low-Moderate Cardiovascular Risk: The NIRVANA Study. Frontiers in Physiology, 2019, 10, 217.	1.3	13
555	Primary Prevention of Cardiovascular Risk in Octogenarians by Risk Factors Control. Current Hypertension Reviews, 2019, 15, 78-84.	0.5	4
556	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. JAMA - Journal of the American Medical Association, 2019, 321, 1069.	3.8	144
557	Pharmacology of Nutraceuticals with Lipid Lowering Properties. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 113-118.	1.0	26
558	Bicuspid aortic valve, atherosclerosis and changes of lipid metabolism: Are there pathological molecular links?. Journal of Molecular and Cellular Cardiology, 2019, 129, 231-235.	0.9	10
559	Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. Frontiers in Cardiovascular Medicine, 2019, 6, 16.	1.1	109
560	2019 ACC/AHA Guideline on the Primary Prevention of CardiovascularÂDisease. Journal of the American College of Cardiology, 2019, 74, e177-e232.	1.2	1,038
561	Latest Updates on Lipid Management. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 85-100.	1.0	5
562	Severe hypertriglyceridaemia and pancreatitis in a patient with lipoprotein lipase deficiency based on mutations in lipoprotein lipase (LPL) and apolipoprotein A5 (APOA5) genes. BMJ Case Reports, 2019, 12, e228199.	0.2	6
563	Prescription of statins in suspected nonâ€alcoholic fatty liver disease and high cardiovascular risk, a populationâ€based study. Liver International, 2019, 39, 1343-1354.	1.9	18
566	Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. Pharmacological Research, 2019, 143, 143-150.	3.1	25
567	Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. Internal and Emergency Medicine, 2019, 14, 621-625.	1.0	37
568	What special considerations must be made for the pharmacotherapeutic management of heterozygous familial hypercholesterolemia?. Expert Opinion on Pharmacotherapy, 2019, 20, 1175-1180.	0.9	1
569	The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Current Atherosclerosis Reports, 2019, 21, 20.	2.0	13
570	Impaired blood glucose levels in patients with dyslipidemia: what are the therapeutic implications? The PREVENDIAB study. Future Cardiology, 2019, 15, 175-182.	0.5	1
571	Prevalence and Control of Dyslipidemia in Patients Referred for High Blood Pressure: The Disregarded â€œDouble-Troubleâ€•Lipid Profile in Overweight/Obese. Advances in Therapy, 2019, 36, 1426-1437.	1.3	30
572	Nutraceutical approach for the management of cardiovascular risk â€“ a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study. Nutrition Journal, 2019, 18, 13.	1.5	37

#	Article	IF	Citations
573	Plasma phospholipid fatty acids are associated with altered fibrin clot properties in a population-based setting. Prostaglandins Leukotrienes and Essential Fatty Acids, 2019, 143, 1-7.	1.0	3
574	Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings . Therapeutics and Clinical Risk Management, 2019, Volume 15, 137-145.	0.9	13
575	Metabolic Alterations in Cardiopulmonary Vascular Dysfunction. Frontiers in Molecular Biosciences, 2018, 5, 120.	1.6	20
576	Race-Based Differences in Lipoprotein(a)-Associated Risk of Carotid Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 523-529.	1.1	40
577	Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovascular Drugs and Therapy, 2019, 33, 69-76.	1.3	11
578	Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-Î± Modulator (SPPARMÎ±), in Dyslipidemic Patients with Renal Impairment. International Journal of Molecular Sciences, 2019, 20, 706.	1.8	53
579	Shuangyu Tiaozhi Granule Attenuates Hypercholesterolemia through the Reduction of Cholesterol Synthesis in Rat Fed a High Cholesterol Diet. BioMed Research International, 2019, 2019, 1-11.	0.9	8
580	Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia â€“ spotlight on volanesorsen. Expert Opinion on Investigational Drugs, 2019, 28, 389-394.	1.9	10
581	Letter regarding the article, “A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients” . Drug Design, Development and Therapy, 2019, Volume 13, 385-386.	2.0	0
582	Multicentre, open-label, randomised controlled clinical trial to assess the efficacy and safety of appropriate target values for lipid management in patients who have mild-to-moderate stenotic lesions with high-risk plaques in coronary arteries: study protocol. BMJ Open, 2019, 9, e022843.	0.8	0
583	Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial. BioMed Research International, 2019, 2019, 1-7.	0.9	11
584	Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study. Advances in Therapy, 2019, 36, 608-620.	1.3	10
585	Associations between the lipid profile and the development of hypertension in young individuals â€“ the preliminary study. Archives of Medical Science, 2019, 18, 25-35.	0.4	4
586	2018 Guidelines for the management of dyslipidemia. Korean Journal of Internal Medicine, 2019, 34, 723-771.	0.7	144
587	Statin adherence and persistence on secondary prevention of cardiovascular disease in Taiwan. Heart Asia, 2019, 11, e011176.	1.1	5
588	Alimentazione, salute e longevitÃ nei pazienti adulti. Italian Journal of Medicine, 2019, , 1-138.	0.2	0
589	Diabetes Mellitus and Acute Coronary Syndrome: A Lethal Combination Requiring Better Therapeutic Strategies. Current Vascular Pharmacology, 2019, 18, 77-79.	0.8	3
590	The atheroprotective roles of heart-protecting musk pills against atherosclerosis development in apolipoprotein E-deficient mice. Annals of Translational Medicine, 2019, 7, 714-714.	0.7	6

#	Article	IF	Citations
591	Relationship between ethanol consumption and TBL2 rs17145738 on LDL-C concentration in Japanese adults: a four season 3-day weighed diet record study. BMC Nutrition, 2019, 5, 61.	0.6	1
592	2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure. Journal of the American College of Cardiology, 2019, 74, 2661-2706.	1.2	33
593	Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: Data from the DISGEN-LIPID study. Revista Portuguesa De Cardiologia (English) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.2	2
594	Adherence To Lipid-Lowering Therapy In Patients With Coronary Heart Disease From The State Of Saxony-Anhalt, Germany . Vascular Health and Risk Management, 2019, Volume 15, 477-483.	1.0	10
595	Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!. Archives of Medical Science, 2019, 15, 1357-1364.	0.4	31
596	Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at â€œExtremeâ€•ASCVD Risk. Current Diabetes Reports, 2019, 19, 146.	1.7	5
597	Đn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria. BMC Health Services Research, 2019, 19, 902.	0.9	2
598	Are the Levels of Lipid Parameters Associated with Biometeorological Conditions?. International Journal of Environmental Research and Public Health, 2019, 16, 4636.	1.2	12
599	Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: Data from the DISGEN-LIPID study. Revista Portuguesa De Cardiologia, 2019, 38, 559-569.	0.2	24
600	Pulse wave velocity as a measure of arterial stiffness in patients with familial hypercholesterolemia: a systematic review and meta-analysis. Archives of Medical Science, 2019, 15, 1365-1374.	0.4	18
601	Association between different lipid parameters and aortic stiffness. Journal of Hypertension, 2019, 37, 2240-2246.	0.3	16
602	The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes. Medicine (United States), 2019, 98, e18510.	0.4	4
603	Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy. Cardiovascular Therapeutics, 2019, 2019, 1-10.	1.1	4
604	The association of metabolic syndrome components and chronic kidney disease in patients with hypertension. Lipids in Health and Disease, 2019, 18, 229.	1.2	35
606	CODAP: A multidisciplinary consensus among Portuguese experts on the definition, detection and management of atherogenic dyslipidemia. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 531-542.	0.2	2
607	Moxibustion for treating patients with hyperlipidemia. Medicine (United States), 2019, 98, e18209.	0.4	6
608	The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it. Cardiovascular Endocrinology and Metabolism, 2019, 8, 14-27.	0.5	18
609	High prevalence of cardiovascular risk factors and insulin resistance 6 years after hyperglycemia first detected in pregnancy in Cape Town, South Africa. BMJ Open Diabetes Research and Care, 2019, 7, e000740.	1.2	6

#	Article	IF	Citations
610	The role of lipoprotein (a) in primary and secondary cardiovascular disease prevention. Current Opinion in Cardiology, 2019, 34, 424-434.	0.8	6
611	Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?. Journal of Clinical Medicine, 2019, 8, 2073.	1.0	15
612	Age-related cardiovascular risk in adult patients with congenital heart disease. International Journal of Cardiology, 2019, 277, 90-96.	0.8	11
613	Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. European Heart Journal, 2019, 40, 2775-2781.	1.0	95
614	Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology, 2019, 51, 148-154.	0.3	113
615	Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. European Heart Journal, 2019, 40, 621-631.	1.0	97
616	ApoB in clinical care: Pro and Con. Atherosclerosis, 2019, 282, 169-175.	0.4	27
617	Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology, 2019, 12, 129-143.	1.3	29
618	Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 225-232.	1.8	30
619	Obesity, Hypertension, and Dyslipidemia. Endocrinology, 2019, , 227-241.	0.1	1
620	Drug Therapy of Dyslipidemia in the Elderly. Drugs and Aging, 2019, 36, 321-340.	1.3	22
621	The effect of chronic physical illnesses on psychiatric hospital admission in patients with recurrent major depression. Psychiatry Research, 2019, 272, 602-608.	1.7	8
622	Patient Characteristics and General Practitionersâ€™ Advice to Stop Statins in Oldest-Old Patients: a Survey Study Across 30 Countries. Journal of General Internal Medicine, 2019, 34, 1751-1757.	1.3	12
623	Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American Heart Journal, 2019, 210, 18-28.	1.2	102
624	Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. Atherosclerosis, 2019, 282, 52-56.	0.4	44
625	Disconcordance between ESC prevention guidelines and observed lipid profiles in patients with known coronary artery disease. IJC Heart and Vasculature, 2019, 22, 73-77.	0.6	12
626	Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial. Journal of Clinical Lipidology, 2019, 13, 138-147.	0.6	14
627	Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC). European Journal of Preventive Cardiology, 2019, 26, 709-727.	0.8	68

#	Article	IF	Citations
628	Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD)â€"Current Considerations for Clinical Practice. Journal of Clinical Medicine, 2019, 8, 69.	1.0	40
629	Lipid paradox in patients with acute myocardial infarction: Potential impact of malnutrition. Clinical Nutrition, 2019, 38, 2311-2318.	2.3	18
630	Koumiss consumption modulates gut microbiota, increases plasma high density cholesterol, decreases immunoglobulin G and albumin. Journal of Functional Foods, 2019, 52, 469-478.	1.6	38
631	Short-Term Effects of Dry Extracts of Artichokeand Berberis in Hypercholesterolemic Patients Without Cardiovascular Disease. American Journal of Cardiology, 2019, 123, 588-591.	0.7	19
632	Low-Grade Inflammation in the Association between Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis: A Study of More Than 115000 Individuals from the General Population. Clinical Chemistry, 2019, 65, 321-332.	1.5	71
633	A clinical prescription for heart health in midlife women. Maturitas, 2019, 119, 46-53.	1.0	4
634	Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia. Current Pharmaceutical Design, 2019, 24, 3647-3653.	0.9	8
635	Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease. Annals of Internal Medicine, 2019, 170, 1.	2.0	126
636	Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clinical Research in Cardiology, 2019, 108, 520-538.	1.5	39
637	Herpes zoster infection and statins: which implications in clinical practice?. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 93-99.	1.3	4
638	Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 47-54.	1.4	16
639	Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis. Rheumatology, 2019, 58, 933-934.	0.9	7
640	World Heart Federation Cholesterol Roadmap. Global Heart, 2017, 12, 179.	0.9	30
641	Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?. European Heart Journal, 2019, 40, 1643-1650.	1.0	72
642	Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelisâ€"Menten Approximation of a Target-Mediated Drug Disposition Modelâ€"Support for a Biologics License Application Submission: Part I. Clinical Pharmacokinetics, 2019, 58, 101-113.	1.6	23
643	Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II. Clinical Pharmacokinetics, 2019, 58, 115-130.	1.6	6
644	Is there sufficient evidence to supplement omega-3 fatty acids to increase muscle mass and strength in young and older adults?. Clinical Nutrition, 2020, 39, 23-32.	2.3	39
645	Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. European Journal of Preventive Cardiology, 2020, 27, 556-558.	0.8	39

#	Article	IF	Citations
646	Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends in Cardiovascular Medicine, 2020, 30, 80-85.	2.3	21
647	The role of nutraceuticals in the treatment of primary dyslipidemia. Hellenic Journal of Cardiology, 2020, 61, 60-62.	0.4	2
648	Cholecystectomy and Biliary Sphincterotomy Increase Fecal Bile Loss and Improve Lipid Profile in Dyslipidemia. Digestive Diseases and Sciences, 2020, 65, 1223-1230.	1.1	7
649	High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 328-330.	1.4	3
651	Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials. Diabetes and Metabolism, 2020, 46, 280-287.	1.4	1
652	Changes in clinical indicators related to the transition from dialysis to kidney transplantationâ€"data from the ERA-EDTA Registry. CKJ: Clinical Kidney Journal, 2020, 13, 188-198.	1.4	1
653	Relationship between serum homocysteine and different menopausal stage. Climacteric, 2020, 23, 59-64.	1.1	5
654	Challenges in reducing atherosclerotic inflammation in patients with familial hypercholesterolemia. European Journal of Preventive Cardiology, 2020, 27, 2099-2101.	0.8	3
655	The predictive role of interleukin 6 trans-signalling in middle-aged men and women at low-intermediate risk of cardiovascular events. European Journal of Preventive Cardiology, 2020, 27, 122-129.	0.8	7
656	Treatment of children with heterozygous familial hypercholesterolemia. International Journal of Cardiology, 2020, 304, 177-178.	0.8	5
657	Recommendations for (Discontinuation of) Statin Treatment in Older Adults: Review of Guidelines. Journal of the American Geriatrics Society, 2020, 68, 417-425.	1.3	38
658	Association of Statin and Its Lipophilicity With Cardiovascular Events in Patients Receiving Chronic Dialysis. Clinical Pharmacology and Therapeutics, 2020, 107, 1312-1324.	2.3	7
659	Microcirculation. , 2020, , .		1
660	Evaluation of health-related quality of life in adults with and without dyslipidaemia in rural areas of central China. Quality of Life Research, 2020, 29, 925-939.	1.5	10
661	Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 282-291.	1.1	44
662	Role of femoral artery ultrasound imaging in cardiovascular event risk prediction in a primary prevention cohort at a medium-term follow-up. Journal of Cardiology, 2020, 75, 537-543.	0.8	17
663	PCSK9 inhibitors: Ratification of the role of LDL cholesterol in cardiovascular prevention. Towards a convergence of European and North American prevention guidelines?. Revista Clínica Espanõla, 2020, 220, 374-382.	0.3	0
664	The development of a theory informed behaviour change intervention to improve adherence to dietary and physical activity treatment guidelines in individuals with familial hypercholesterolaemia (FH). BMC Health Services Research, 2020, 20, 27.	0.9	13

#	Article	IF	Citations
665	Pasta Consumption and Connected Dietary Habits: Associations with Glucose Control, Adiposity Measures, and Cardiovascular Risk Factors in People with Type 2 Diabetesâ€"TOSCA.IT Study. Nutrients, 2020, 12, 101.	1.7	17
666	The effects of grape seed extract on glycemic control, serum lipoproteins, inflammation, and body weight: A systematic review and metaâ€analysis of randomized controlled trials. Phytotherapy Research, 2020, 34, 239-253.	2.8	34
667	Familial hypercholesterolemia: A complex genetic disease with variable phenotypes. European Journal of Medical Genetics, 2020, 63, 103831.	0.7	51
668	An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 115-121.	1.4	46
669	ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. Journal of Clinical Lipidology, 2020, 14, 98-108.e8.	0.6	23
670	Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. American Heart Journal, 2020, 220, 82-88.	1.2	3
671	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. International Journal of Cardiology, 2020, 299, 289-295.	0.8	1
672	Recent developments in pharmacotherapy for hypertriglyceridemia: whatâ€™s the current state of the art?. Expert Opinion on Pharmacotherapy, 2020, 21, 107-120.	0.9	10
673	Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study. Diabetes Therapy, 2020, 11, 453-465.	1.2	1
674	Genetic disorders of lipoprotein metabolism. , 2020, , 245-265.		0
675	PCSK9 Inhibitorsâ€™ New Users: Analysis of Prescription Patterns and Patientsâ€™ Characteristics from an Italian Real-world Study. Clinical Drug Investigation, 2020, 40, 173-181.	1.1	21
676	Effects of 2 Types of Resistance Training Models on Obese Adolescents' Body Composition, Cardiometabolic Risk, and Physical Fitness. Journal of Strength and Conditioning Research, 2020, 34, 2672-2682.	1.0	24
677	Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group. Molecular Genetics and Metabolism, 2020, 129, 59-66.	0.5	17
678	Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect. Metabolites, 2020, 10, 391.	1.3	9
679	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. The Cochrane Library, 2020, 2020, CD011748.	1.5	42
680	Exposure to ambient air pollution and blood lipids in children and adolescents: A national population based study in China. Environmental Pollution, 2020, 266, 115422.	3.7	28
681	Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 31-38.	1.8	13
682	Effects of Two Community-Based Exercise Programs on Adherence, Cardiometabolic Markers, and Body Composition in Older People with Cardiovascular Risk Factors: A Prospective Observational Cohort Study. Journal of Personalized Medicine, 2020, 10, 176.	1.1	1

#	Article	IF	Citations
683	Is There a Nonlinear Relationship between Serum Uric Acid and Lipids in a Hypertensive Population with eGFR â‰¥30â€‰ml/min/1.73â€‰m²? Findings from the China Hypertension Registry Study. International Journal of Endocrinology, 2020, 2020, 1-7.	0.6	5
684	Type 2 diabetes in older patients: an analysis of the DPV and DIVE databases. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882095829.	1.4	7
685	Comparison of low-density lipoprotein cholesterol level calculated using the modified Martin/Hopkins estimation or the Friedewald formula with direct homogeneous assay measured low-density lipoprotein cholesterol. Archives of Medical Science, 2020, 18, 577-586.	0.4	2
686	Multiple functions of policosanol in elderly patients with dyslipidemia. Journal of International Medical Research, 2020, 48, 030006052093608.	0.4	4
687	Effect of one-anastomosis gastric bypass on cardiovascular risk factors in patients with vitamin D deficiency and morbid obesity: A secondary analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2379-2388.	1.1	2
688	Insulin Resistance Predicts Severity of Coronary Atherosclerotic Disease in Non-Diabetic Patients. Journal of Clinical Medicine, 2020, 9, 2144.	1.0	15
689	A high triglyceride glucose index is more closely associated with hypertension than lipid or glycemic parameters in elderly individuals: a cross-sectional survey from the Reaction Study. Cardiovascular Diabetology, 2020, 19, 112.	2.7	58
690	The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico. IJC Heart and Vasculature, 2020, 29, 100545.	0.6	6
691	A Comprehensive Update on the Chylomicronemia Syndrome. Frontiers in Endocrinology, 2020, 11, 593931.	1.5	60
692	A Novel Promising Frontier for Human Health: The Beneficial Effects of Nutraceuticals in Cardiovascular Diseases. International Journal of Molecular Sciences, 2020, 21, 8706.	1.8	32
693	Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome. Journal of Cardiovascular Pharmacology, 2020, 76, 658-670.	0.8	9
694	Analysis of Arterial Stiffness and Sexual Function after Adding on PCSK9 Inhibitor Treatment in Male Patients with Familial Hypercholesterolemia: A Single Lipid Center Real-World Experience. Journal of Clinical Medicine, 2020, 9, 3597.	1.0	10
695	Effect of Changes in Patientâ€™s Self-management Strategies on Clinical Outcomes: Evidence from a Cohort Study of Patients with Diabetes, Hypertension, and Hyperlipidemia. International Journal of Behavioral Medicine, 2021, 28, 479-487.	0.8	4
696	The Effect of Blood Lipids on the LeftÂVentricle. Journal of the American College of Cardiology, 2020, 76, 2477-2488.	1.2	26
697	Plasma Levels of Occludin and Claudin-5 in Acute Stroke Are Correlated with the Type and Location of Stroke but Not with the Neurological State of Patientsâ€”Preliminary Data. Brain Sciences, 2020, 10, 831.	1.1	13
698	Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia. Cardiology and Therapy, 2020, 9, 323-332.	1.1	16
699	Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy. Annals of Medicine, 2020, 52, 462-470.	1.5	12
700	Relationship between Lipid Profiles and Glycemic Control Among Patients with Type 2 Diabetes in Qingdao, China. International Journal of Environmental Research and Public Health, 2020, 17, 5317.	1.2	18

#	Article	IF	Citations
702	Metabolic control achievement in a population with premature coronary artery disease: results of the genetics of atherosclerotic disease study. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882094337.	1.4	5
703	Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017. Journal of Clinical Medicine, 2020, 9, 3398.	1.0	1
704	Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey. Archives of Medical Science, 2020, 16, 1279-1287.	0.4	11
705	Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type. International Journal of Environmental Research and Public Health, 2020, 17, 6309.	1.2	0
706	Stroke in the adult Qatari population (Q-stroke) a hospital-based retrospective cohort study. PLoS ONE, 2020, 15, e0238865.	1.1	10
707	Association of Hypertriglyceridemia with Allâ€Cause Mortality and Atherosclerotic Cardiovascular Events in a Lowâ€Risk Italian Population: The TGâ€REAL Retrospective Cohort Analysis. Journal of the American Heart Association, 2020, 9, e015801.	1.6	38
708	Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study. BMC Cardiovascular Disorders, 2020, 20, 418.	0.7	5
709	Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. Clinical Research in Cardiology, 2022, 111, 243-252.	1.5	32
710	Evaluation of Glycemic Index Education in People Living with Type 2 Diabetes: Participant Satisfaction, Knowledge Uptake, and Application. Nutrients, 2020, 12, 2416.	1.7	4
711	Evaluation of the Pharmacokinetic Drugâ€"Drug Interaction between Micronized Fenofibrate and Pitavastatin in Healthy Volunteers. Pharmaceutics, 2020, 12, 869.	2.0	4
712	Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Lowâ€Density Lipoprotein Cholesterolâ€"The Framingham Heart Study. Journal of the American Heart Association, 2020, 9, e014711.	1.6	22
713	A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension. Journal of Hypertension, 2020, 38, 1890-1898.	0.3	8
714	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. European Heart Journal, 2020, 41, 4114-4123.	1.0	35
715	Translating science into guidance on the management of dyslipidaemias. Atherosclerosis, 2020, 315, 145-147.	0.4	0
716	Cis- and Trans-Palmitoleic Acid Isomers Regulate Cholesterol Metabolism in Different Ways. Frontiers in Pharmacology, 2020, 11, 602115.	1.6	11
717	PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects. Frontiers in Physiology, 2020, 11, 595819.	1.3	49
718	Case Report: Liver Transplantation in Homozygous Familial Hypercholesterolemia (HoFH)â€"Long-Term Follow-Up of a Patient and Literature Review. Frontiers in Pediatrics, 2020, 8, 567895.	0.9	12
719	Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study. Cardiovascular Drugs and Therapy, 2020, 34, 515-523.	1.3	2

#	Article	IF	Citations
720	Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease. Frontiers in Pharmacology, 2020, 11, 675.	1.6	2
721	Major Lipids, Apolipoproteins, and Alterations of Gut Microbiota. Journal of Clinical Medicine, 2020, 9, 1589.	1.0	21
722	A double-blind, placebo-controlled clinical trial to assess the effects of a combined nutraceutical on endothelial function in patients with mild-to-moderate hypercholesterolaemia. Archives of Medical Sciences Atherosclerotic Diseases, 2020, 5, 36-42.	0.5	3
723	Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country. BMC Rheumatology, 2020, 4, 42.	0.6	10
724	Therapeutic Potential of Quercetin as an Antiatherosclerotic Agent in Atherosclerotic Cardiovascular Disease: A Review. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-12.	0.5	47
725	GuÃas de prevenciÃ³n cardiovascular de sociedades cientÃficas y administraciones sanitarias: la necesidad de convergencia. Revista Clinica Espanola, 2020, 220, 294-296.	0.2	0
726	Dyslipidaemias and their treatment in high complexity centres in Colombia. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2020, 32, 101-110.	0.1	2
727	How well do laboratories adhere to recommended guidelines for dyslipidaemia management in Europe? The CArdiac MARker Guideline Uptake in Europe (CAMARGUE) study. Clinica Chimica Acta, 2020, 508, 267-272.	0.5	13
728	Low-density lipoprotein cholesterol levels among individuals experiencing statin-associated symptoms: Data from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Journal of Clinical Lipidology, 2020, 14, 720-729.	0.6	2
729	Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: Results from the Rotterdam Study. Atherosclerosis, 2020, 299, 64-66.	0.4	2
730	Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids in Health and Disease, 2020, 19, 42.	1.2	133
731	Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine, 2020, 382, 1507-1519.	13.9	758
732	Serum Zinc-Î±2-Glycoprotein Levels in Patients with or without Coronary Artery Disease in Chinese North Population. International Journal of Endocrinology, 2020, 2020, 1-9.	0.6	2
733	Does lipid-lowering medication improve cardiac sympathetic nerve integrity?. Journal of Nuclear Cardiology, 2021, 28, 1458-1460.	1.4	1
734	Polygenic Hyperlipidemias and Coronary Artery Disease Risk. Circulation Genomic and Precision Medicine, 2020, 13, e002725.	1.6	60
735	Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: Data from the Brisighella Heart Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 907-914.	1.1	27
736	The predictive study of the relation between elevated low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and mortality in peritoneal dialysis. Lipids in Health and Disease, 2020, 19, 51.	1.2	11
737	Establishment and Validation of a Risk Prediction Model for Early Diabetic Kidney Disease Based on a Systematic Review and Meta-Analysis of 20 Cohorts. Diabetes Care, 2020, 43, 925-933.	4.3	91

#	Article	IF	Citations
738	Carotid and Femoral Atherosclerotic Plaques in Asymptomatic and Non-Treated Subjects: Cardiovascular Risk Factors, 10-Years Risk Scores, and Lipid Ratiosâ€™ Capability to Detect Plaque Presence, Burden, Fibro-Lipid Composition and Geometry. Journal of Cardiovascular Development and Disease, 2020, 7, 11.	0.8	11
739	Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia. Journal of Lipid and Atherosclerosis, 2020, 9, 162.	1.1	6
740	Effect of 12-Week Interventions Involving Nordic Walking Exercise and a Modified Diet on the Anthropometric Parameters and Blood Lipid Profiles in Overweight and Obese Ex-Coal Miners. Obesity Facts, 2020, 13, 201-212.	1.6	9
741	PCSK9 Protein and rs562556 Polymorphism Are Associated With Arterial Plaques in Healthy Middleâ€Aged Population: The STANISLAS Cohort. Journal of the American Heart Association, 2020, 9, e014758.	1.6	15
742	Effects of a Milk-Based Meal Replacement Program on Weight and Metabolic Characteristics in Adults with Severe Obesity . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 197-205.	1.1	10
743	Effect of Berberine on Atherosclerosis and Gut Microbiota Modulation and Their Correlation in High-Fat Diet-Fed ApoEâ^'/â^' Mice. Frontiers in Pharmacology, 2020, 11, 223.	1.6	129
744	Efficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 423-431.	1.1	4
745	Effects of a novel nutraceutical combination (BruMeCholâ„¢) in subjects with mild hypercholesterolemia: study protocol of a randomized, double-blind, controlled trial. Trials, 2020, 21, 616.	0.7	9
746	Atherosclerotic Extension of Carotid Arteries: An Insertion in Clinical Practice. International Journal of Vascular Medicine, 2020, 2020, 1-8.	0.4	1
747	Molecular and Biological Functions of Quercetin as a Natural Solution for Cardiovascular Disease Prevention and Treatment. Plant Foods for Human Nutrition, 2020, 75, 307-315.	1.4	37
748	A novel selective PPARÎ± modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms. PLoS ONE, 2020, 15, e0235362.	1.1	12
749	Patients with the Subcortical Small Vessel Type of Dementia Have Disturbed Cardiometabolic Risk Profile. Journal of Alzheimer's Disease, 2020, 73, 1373-1383.	1.2	2
750	Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis . Drug Design, Development and Therapy, 2020, Volume 14, 157-165.	2.0	14
751	Altered adipocytokine profile predicts early stage of left ventricular remodeling in hypertensive patients with type 2 diabetes mellitus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 109-116.	1.8	7
752	Framingham Risk Stratification of Middle-Aged Migraineurs. Behavioural Neurology, 2020, 2020, 1-5.	1.1	2
753	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. European Journal of Preventive Cardiology, 2020, 27, 1663-1674.	0.8	9
754	Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule. Journal of Lipids, 2020, 2020, 1-26.	1.9	50
755	Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. CKJ: Clinical Kidney Journal, 2020, 13, 753-757.	1.4	20

#	Article	IF	Citations
756	Significance of blood lipid parameters as effective markers for arteriogenic erectile dysfunction. Andrology, 2020, 8, 1086-1094.	1.9	16
757	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovascular Diabetology, 2020, 19, 14.	2.7	22
758	Associations between urinary cadmium levels, blood pressure, and hypertension: the ESTEBAN survey. Environmental Science and Pollution Research, 2020, 27, 10748-10756.	2.7	33
759	The role of hepcidin and iron homeostasis in atherosclerosis. Pharmacological Research, 2020, 153, 104664.	3.1	64
760	Associations between age and dyslipidemia are differed by education level: The Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) cohort. Lipids in Health and Disease, 2020, 19, 12.	1.2	29
761	Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 307-315.	1.0	4
762	Low-density lipoprotein cholesterol goal attainment rates in high-risk patients with cardiovascular diseases and diabetes mellitus in Korea: a retrospective cohort study. Lipids in Health and Disease, 2020, 19, 5.	1.2	20
763	The Clinical Outcomes Based on the Achievement of Low-Density Lipoprotein Cholesterol Targets after ST Elevation Myocardial Infarction. Journal of Clinical Medicine, 2020, 9, 79.	1.0	2
764	Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension. Cardiology and Therapy, 2020, 9, 19-34.	1.1	18
765	Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries. Cardiovascular Therapeutics, 2020, 2020, 1-8.	1.1	7
766	Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in Hypertriglyceridemia. Journal of the Endocrine Society, 2020, 4, bvz010.	0.1	4
768	The Role of Cardiovascular Risk Assessment in Preventive Medicine: A Perspective from Portugal Primary Health-Care Cardiovascular Risk Assessment. Journal of Environmental and Public Health, 2020, 2020, 1-7.	0.4	9
769	Metabolic profiles among COPD and controls in the CanCOLD population-based cohort. PLoS ONE, 2020, 15, e0231072.	1.1	4
770	Performance of risk prediction scores for cardiovascular mortality in older persons: External validation of the SCORE OP and appraisal. PLoS ONE, 2020, 15, e0231097.	1.1	4
771	Diet, Lifestyle, Smoking. Handbook of Experimental Pharmacology, 2020, , 1.	0.9	5
772	Coronary Artery Calcium and the Age-Specific Competing Risk of Cardiovascular Versus Cancer Mortality: The Coronary Artery Calcium Consortium. American Journal of Medicine, 2020, 133, e575-e583.	0.6	12
773	The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2020, 32, 581-587.	0.8	4
774	Lifetime risk assessment in cholesterol management among hypertensive patients: observational cross-sectional study based on electronic health record data. BMC Family Practice, 2020, 21, 62.	2.9	2

#	Article	IF	Citations
775	Nutrition and physical activity intervention for families with familial hypercholesterolaemia: protocol for a pilot randomised controlled feasibility study. Pilot and Feasibility Studies, 2020, 6, 42.	0.5	4
776	Comparison of Lipid Profile, Liver Enzymes, Creatine Kinase and Lactate Dehydrogenase Among Type II Diabetes Mellitus Patients on Statin Therapy . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 763-773.	1.1	11
777	Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe() mice. Acta Pharmaceutica Sinica B, 2020, 10, 1769-1783.	5.7	26
778	Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the â€œPrime Timeâ€•of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?. Cardiovascular Drugs and Therapy, 2021, 35, 467-477.	1.3	18
779	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy. JAMA Cardiology, 2021, 6, 139.	3.0	50
780	Dyslipidaemia after switch to tenofovir alafenamide (TAF)â€based cART regimens in a cohort of HIVâ€positive patients: what clinical relevance?. HIV Medicine, 2021, 22, 140-145.	1.0	12
781	Low-density lipoprotein aggregation predicts adverse cardiovascular events in peripheral artery disease. Atherosclerosis, 2021, 316, 53-57.	0.4	13
782	Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial. Phytotherapy Research, 2021, 35, 2045-2056.	2.8	15
783	â€œCerebral small vessel disease and other influential factors of cognitive impairment in the middle-aged: a long-term observational cohort PURE-MIND study in Polandâ€• GeroScience, 2021, 43, 279-295.	2.1	17
784	Lipid reference values in an Irish population. Irish Journal of Medical Science, 2021, 190, 117-127.	0.8	7
785	Management of Familial Hypercholesterolemia: Current Status and Future Perspectives. Journal of the Endocrine Society, 2021, 5, bvaa122.	0.1	20
786	Association of the Estimated Coronary Artery Incidence Risk According to the Japan Atherosclerosis Society Guidelines 2017 with Cardio-Ankle Vascular Index. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1266-1274.	0.9	3
787	The Estimated Absolute Risk of Coronary Artery Disease and Subclinical Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1260-1262.	0.9	0
788	Development and Validation of Retinal Vasculature Nomogram in Suspected Angina Due to Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2022, 29, 579-596.	0.9	8
789	Association between cumulative exposure to different lipid parameters and risk of newly developed carotid plaque. Stroke and Vascular Neurology, 2021, 6, 359-365.	1.5	8
790	An association between rs7635818 polymorphism located on chromosome 3p12.3 and the presence of abdominal aortic aneurysm. Physiological Research, 2021, 70, 193-201.	0.4	3
791	Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus. Renal Failure, 2021, 43, 477-487.	0.8	9
792	Effect of a novel functional tomato sauce (OsteoCol) from vine-ripened tomatoes on serum lipids in individuals with common hypercholesterolemia: tomato sauce and hypercholesterolemia. Journal of Translational Medicine, 2021, 19, 19.	1.8	8

#	Article	IF	Citations
793	SCORE underestimates cardiovascular mortality in hypertension: insight from the OLD-HTA and NEW-HTA Lyon cohorts. European Journal of Preventive Cardiology, 2022, 29, 136-143.	0.8	4
794	Nutraceuticals and Cardiovascular Disease. Contemporary Cardiology, 2021, , 67-87.	0.0	0
795	Therapeutic implications of statins in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction: a review of current literature. F1000Research, 0, 10, 16.	0.8	0
797	Evaluation of atherogenic lipoprotein-cholesterol to HDL cholesterol ratio as a prognostic test for ST-segment elevation myocardial infarction. International Journal of Medical Sciences, 2021, 18, 2897-2904.	1.1	0
798	Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1307-1322.	0.9	5
799	High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study. Journal of Atherosclerosis and Thrombosis, 2021, , .	0.9	2
800	Chronic lung diseases: prospects for regeneration and repair. European Respiratory Review, 2021, 30, 200213.	3.0	16
801	Determination of Small and Dense of Low-Density Lipoprotein and Coronary Heart Disease. Advances in Clinical Medicine, 2021, 11, 3525-3528.	0.0	0
802	Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk. Journal of Nutritional Science, 2021, 10, e75.	0.7	25
803	Future Perspectives in Nutraceutical Research. Contemporary Cardiology, 2021, , 289-293.	0.0	0
804	Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib. Current Oncology, 2021, 28, 265-272.	0.9	7
805	Spatially Weighted Calcium Score Beyond Power of Zero. Circulation: Cardiovascular Imaging, 2021, 14, e012236.	1.3	0
806	Relationship Between Non-fasting Triglycerides and Cardiovascular Disease Mortality in a 20-year Follow-up Study of a Japanese General Population: NIPPON DATA90. Journal of Epidemiology, 2022, 32, 303-313.	1.1	9
807	Gender differences in nutrition literacy levels among university students and employees: a descriptive study. Journal of Nutritional Science, 2021, 10, e56.	0.7	15
808	Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study â€" preliminary results. Cardiology Journal, 2021, 28, 58-66.	0.5	2
809	Prevalence of atherosclerosis risk factors in Egyptian patients with acute coronary syndrome: final data of the nationwide cross-sectional â€˜CardioRiskâ€™ project. Journal of Public Health in Africa, 2020, 11, 1368.	0.2	1
810	Familial Hypercholesterolemia: Update and Review. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, .	0.6	2
811	Lipoprotein apheresis efficacy and challenges: single center experience. Hematology, Transfusion and Cell Therapy, 2022, 44, 56-62.	0.1	3

#	Article	IF	Citations
812	Effects of vitamin D supplementation on apolipoprotein A1 and B100 levels in adults: Systematic review and meta-analysis of controlled clinical trials. Journal of Cardiovascular and Thoracic Research, 2021, 13, 190-197.	0.3	7
814	Optimization of the Statin Therapy Algorithm in Outpatient Practice: Adherence and Economic Benefits. Rational Pharmacotherapy in Cardiology, 2021, 17, 49-55.	0.3	1
815	PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis. Archives of Medical Science, 2021, 17, 1365-1377.	0.4	39
816	Prevention starts from the crib: the pediatric point of view on detection of families at high cardiovascular risk. Italian Journal of Pediatrics, 2021, 47, 51.	1.0	6
817	Phytonutrient supplements and metabolic biomarkers of cardiovascular disease: An umbrella review of metaâ€analyses of clinical trials. Phytotherapy Research, 2021, 35, 4171-4182.	2.8	4
818	Provider Teams Outperform Solo Providers In Managing Chronic Diseases And Could Improve The Value Of Care. Health Affairs, 2021, 40, 435-444.	2.5	24
819	Remnant Cholesterol and Common Carotid Artery Intima-Media Thickness in Patients With Ischemic Stroke. Circulation: Cardiovascular Imaging, 2021, 14, e010953.	1.3	36
820	Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated with Nutraceuticals Derived from Red Yeast Rice. Cardiovascular Therapeutics, 2021, 2021, 1-8.	1.1	2
821	Preliminary Results of CitraVesâ„¢ Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study. Metabolites, 2021, 11, 276.	1.3	18
822	Role of endometriosis in defining cardiovascular risk: a gender medicine approach for womenâ€™s health. Human Fertility, 2022, 25, 745-753.	0.7	9
823	Regulation of Apolipoprotein B by Natural Products and Nutraceuticals: A Comprehensive Review. Current Medicinal Chemistry, 2021, 28, 1363-1406.	1.2	13
824	Focal pericoronary adipose tissue attenuation is related to plaque presence, plaque type, and stenosis severity in coronary CTA. European Radiology, 2021, 31, 7251-7261.	2.3	19
825	The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 919-924.	0.6	5
826	SR-B1, a Key Receptor Involved in the Progression of Cardiovascular Disease: A Perspective from Mice and Human Genetic Studies. Biomedicines, 2021, 9, 612.	1.4	20
827	Hypertriglyceridemia and Other Plasma Lipid Profile Abnormalities among People Living with Diabetes Mellitus in Ethiopia: A Systematic Review and Meta-Analysis. BioMed Research International, 2021, 2021, 1-12.	0.9	1
828	The use of blood biomarkers in precision medicine for the primary prevention of atherosclerotic cardiovascular disease: a review. Expert Review of Precision Medicine and Drug Development, 2021, 6, 247-258.	0.4	11
829	Circulating bacterial signature is linked to metabolic disease and shifts with metabolic alleviation after bariatric surgery. Genome Medicine, 2021, 13, 105.	3.6	14
830	Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study. Kidney International Reports, 2021, 6, 1661-1668.	0.4	12

#	Article	IF	Citations
831	Effect of Interaction Between Slow Wave Sleep and Obstructive Sleep Apnea on Insulin Resistance: A Large-Scale Study. Nature and Science of Sleep, 2021, Volume 13, 739-749.	1.4	6
832	A study protocol of a randomized trial evaluating the effect of using defined menu plans within an intensive personal nutritional counseling program on cardiovascular risk factors: The MoKaRi (modulation of cardiovascular risk factors) trial. Contemporary Clinical Trials Communications, 2021, 22, 100761.	0.5	3
833	The Genetic Basis of Hypertriglyceridemia. Current Atherosclerosis Reports, 2021, 23, 39.	2.0	17
834	Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf FH Registry. PLoS ONE, 2021, 16, e0251560.	1.1	17
835	Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. European Heart Journal, 2021, 42, 4324-4332.	1.0	135
836	Nutritional Approach to Prevention and Treatment of Cardiovascular Disease in Childhood. Nutrients, 2021, 13, 2359.	1.7	16
837	The effect of PCSK9 inhibitors on brain stroke prevention: AÂsystematic review and meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2234-2243.	1.1	8
838	ALERT-LDL: adherence to guidelines in the treatment of patients with dyslipidemia. Internal and Emergency Medicine, 2021, , 1.	1.0	2
839	Associations Between Macronutrients From Different Dietary Sources and Serum Lipids in 24 639 UK Biobank Study Participants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2190-2200.	1.1	11
840	Effects of canagliflozin on human myocardial redox signalling: clinical implications. European Heart Journal, 2021, 42, 4947-4960.	1.0	57
841	Correlation Between Calcification Characteristics of Carotid Atherosclerotic Plaque and Plaque Vulnerability. Therapeutics and Clinical Risk Management, 2021, Volume 17, 679-690.	0.9	8
842	Comparison of Formula-Based Methods with Diverse TGL: VLDL-C Ratio for Calculating LDL-C in a Tertiary Care Hospital. Journal of Laboratory Physicians, 0, , .	0.4	0
843	Non-fasting lipid profile for cardiovascular risk assessments using China ASCVD risk estimator and Europe SCORE risk charts in Chinese participants. Cardiovascular Diagnosis and Therapy, 2021, 11, 991-1001.	0.7	1
844	KardiyovaskÃ¼ler HastalÄ±klarda SaÄŸlÄ±klÄ± Beslenme Ã–nerileri. Harran Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , 342-348.	0.1	1
845	Moderate excess alcohol consumption and adverse cardiac remodelling in dilated cardiomyopathy. Heart, 2022, 108, 619-625.	1.2	6
846	How to Use Statins in Secondary Prevention of Atherosclerotic Diseases: from the Beneficial Early Initiation to the Potentially Unfavorable Discontinuation. Cardiovascular Drugs and Therapy, 2021, , 1.	1.3	1
847	Determinants of Non-Adherence to the Medications for Dyslipidemia: A Systematic Review. Patient Preference and Adherence, 2021, Volume 15, 1853-1871.	0.8	11
848	Identification and Functional Characterization of a Low-Density Lipoprotein Receptor Gene Pathogenic Variant in Familial Hypercholesterolemia. Frontiers in Genetics, 2021, 12, 650077.	1.1	2

#	Article	IF	Citations
849	Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor Î± Modulator (SPPARMÎ±) in Japanese Patients with Renal Impairment and Dyslipidemia. Internal Medicine, 2021, 60, 2741-2748.	0.3	1
850	Nuclear Magnetic Resonance Spectroscopy in Clinical Metabolomics and Personalized Medicine: Current Challenges and Perspectives. Frontiers in Molecular Biosciences, 2021, 8, 698337.	1.6	44
851	The impact of antihypertensive treatment initiation on health-related quality of life and cardiovascular risk factor levels: a prospective, interventional study. BMC Cardiovascular Disorders, 2021, 21, 444.	0.7	0
852	Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia. PharmacoEconomics - Open, 2022, 6, 277-291.	0.9	3
853	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€”a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2021, 42, 4791-4806.	1.0	303
854	The association of lipid ratios with hyperuricemia in a rural Chinese hypertensive population. Lipids in Health and Disease, 2021, 20, 121.	1.2	4
855	Low prevalence of diabetic retinopathy in patients with long-term type 1 diabetes and current good glycemic control - one-center retrospective assessment. Endocrine, 2022, 75, 427-436.	1.1	3
856	Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe. Advances in Therapy, 2021, 38, 5270-5285.	1.3	19
857	A prediction model based on platelet parameters, lipid levels, and angiographic characteristics to predict in-stent restenosis in coronary artery disease patients implanted with drug-eluting stents. Lipids in Health and Disease, 2021, 20, 118.	1.2	8
858	Lipid management across Europe in the real-world setting: a rapid evidence review. Current Medical Research and Opinion, 2021, 37, 2049-2059.	0.9	18
859	Cost-effectiveness of cascade genetic testing for familial hypercholesterolemia in the United States: A simulation analysis. American Journal of Preventive Cardiology, 2021, 8, 100245.	1.3	15
860	Improved Hypertension by Investigating Circadian Rhythm of Blood Pressure. Edelweiss Journal of Biomedical Research and Review, 2021, , 1-4.	0.4	1
861	The Priority of Non-HDL-C Assessment to Predict New Lesions among Stable Angina Patients with Strong Statins. Journal of Atherosclerosis and Thrombosis, 2021, , .	0.9	0
862	Small Dense Low-Density Lipoprotein Cholesterol is a Potential Marker for Predicting Laser Treatment for Retinopathy in Diabetic Patients. Journal of Atherosclerosis and Thrombosis, 2021, , .	0.9	6
863	Natural products: The role and mechanism in lowâ€density lipoprotein oxidation and atherosclerosis. Phytotherapy Research, 2021, 35, 2945-2967.	2.8	43
864	Nutraceuticals and Lipid Management. Contemporary Cardiology, 2021, , 173-189.	0.0	1
865	ActualizaciÃ³n de las tablas de planificaciÃ³n terapÃ©utica hipocolesterolemiante orientadas a la obtenciÃ³n de los objetivos terapÃ©uticos. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 271-277.	0.4	13
866	Las dislipidemias y su tratamiento en centros de alta complejidad en Colombia. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2020, 32, 101-110.	0.4	3

#	Article	IF	Citations
867	Management of patients with statin intolerance. Atherosclerosis Supplements, 2017, 30, 33-37.	1.2	11
868	Inhibidores de PCSK9: ratificaciÃ³n del papel del colesterol LDL en prevenciÃ³n cardiovascular. Â¿Hacia la convergencia en las guÃas de prevenciÃ³n europeas y norteamericanas?. Revista Clinica Espanola, 2020, 220, 374-382.	0.2	5
869	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2020, 41, 2313-2330.	1.0	776
870	Comparison of pleiotropic effects of statins vs fibrates on laboratory parameters in patients with dyslipidemia. Medicine (United States), 2020, 99, e23427.	0.4	5
871	Is there any role of renin-angiotensin system inhibitors in modulating inflammatory bowel disease outcome?. European Journal of Gastroenterology and Hepatology, 2021, 33, 364-371.	0.8	12
872	Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management. Obesity Facts, 2017, 10, 597-632.	1.6	265
873	The rate of patients at high risk for cardiovascular disease with an optimal low-density cholesterol level: a multicenter study from Thailand. Journal of Geriatric Cardiology, 2019, 16, 344-353.	0.2	2
874	Clustering of Mental and Physical Comorbidity and the Risk of Frailty in Patients Aged 60 Years or More in Primary Care. Medical Science Monitor, 2019, 25, 6820-6835.	0.5	23
875	The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers. Journal of Lipid and Atherosclerosis, 2019, 8, 173.	1.1	19
876	Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors. Journal of Lipid and Atherosclerosis, 2019, 8, 183.	1.1	16
877	Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea. Journal of Lipid and Atherosclerosis, 2019, 8, 242.	1.1	10
878	Primary prevention of cardiovascular disease in older adults in China. World Journal of Clinical Cases, 2017, 5, 349.	0.3	13
879	Relationship between non-alcoholic fatty liver disease and coronary heart disease. World Journal of Clinical Cases, 2020, 8, 4688-4699.	0.3	21
880	Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor Î± modular (SPPARMÎ±), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury. PLoS ONE, 2020, 15, e0241195.	1.1	12
881	Ezetimibe Monotherapy Reduces Serum Levels of Platelet-Activating Factor Acetylhydrolase in Patients With Dyslipidemia. Journal of Clinical Medicine Research, 2019, 11, 676-681.	0.6	3
882	Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction. Anatolian Journal of Cardiology, 2019, 22, 240-249.	0.5	12
883	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. European Cardiology Review, 2020, 15, 1-9.	0.7	38
884	Association between thePINX1andNAT2polymorphisms and serum lipid levels. Oncotarget, 2017, 8, 114081-114094.	0.8	4

#	Article	IF	Citations
885	Studying the Possibility of Optimizing the Statin Therapy Algorithm in Outpatient Practice. Rational Pharmacotherapy in Cardiology, 2020, 16, 528-535.	0.3	5
886	Circulating micro ribonucleic acids in cardiovascular disease: a look beyond myocardial injury. Annals of Translational Medicine, 2016, 4, S30-S30.	0.7	30
887	The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Pharmaceutical Design, 2019, 25, 3266-3281.	0.9	8
888	Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate. Current Pharmaceutical Design, 2020, 25, 4725-4734.	0.9	6
889	Statins: Pharmacokinetics, Pharmacodynamics and Cost-Effectiveness Analysis. Current Vascular Pharmacology, 2019, 17, 213-221.	0.8	7
890	Mapping the Evidence on the Effectiveness of Telemedicine Interventions in Diabetes, Dyslipidemia, and Hypertension: An Umbrella Review of Systematic Reviews and Meta-Analyses. Journal of Medical Internet Research, 2020, 22, e16791.	2.1	141
891	Higher Responsiveness to Rosuvastatin in Polygenic versus Monogenic Hypercholesterolemia: A Propensity Score Analysis. Life, 2020, 10, 73.	1.1	9
892	Dietary Strategies for Metabolic Syndrome: A Comprehensive Review. Nutrients, 2020, 12, 2983.	1.7	181
893	Hypolipidemic treatment and target values of lipids. Interni Medicina Pro Praxi, 2018, 20, 82-84.	0.0	1
894	Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study. Korean Journal of Internal Medicine, 2019, 34, 1252-1262.	0.7	4
895	Trends in Lipids Level and Dyslipidemia among Chinese Adults, 2002-2015. Biomedical and Environmental Sciences, 2019, 32, 559-570.	0.2	33
896	Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Diabetes and Metabolism Journal, 2020, 44, 78.	1.8	7
897	Pre-existing Depression among Newly Diagnosed Dyslipidemia Patients and Cardiovascular Disease Risk. Diabetes and Metabolism Journal, 2020, 44, 307.	1.8	9
898	Neuroprotective effects of statins against amyloid Î²-induced neurotoxicity. Neural Regeneration Research, 2018, 13, 198.	1.6	31
899	Obesity, Cardiac Remodeling, and Metabolic Profile: Validation of a New Simple Index beyond Body Mass Index. Journal of Cardiovascular Echography, 2018, 28, 18.	0.1	20
900	Awareness of physicians and clinical pharmacists about ACC/AHA guidelines for dyslipidemia management: A cross sectional study. Journal of Pharmacy and Bioallied Sciences, 2019, 11, 181.	0.2	6
901	Association of dyslipidemia, hypertension and overweight/obesity with work shift and duration of employment among police officers in a small town in Northeastern Brazil. Revista Brasileira De Medicina Do Trabalho, 2019, 17, 537-544.	0.1	11
902	Effect of FIXed-dose combination of ARb and statin on adherence and risk factor control: The randomized FIXAR study. Cardiology Journal, 2020, , .	0.5	6

#	Article	IF	Citations
903	Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin. Drugs in Context, 2020, 9, 1-11.	1.0	3
904	Therapeutic management of hyperlipoproteinemia (a). Drugs in Context, 2019, 8, 1-11.	1.0	14
905	The association between serum lipids and risk of premature mortality in Latin America: a systematic review of population-based prospective cohort studies. PeerJ, 2019, 7, e7856.	0.9	1
906	Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretestâ€“Post-Test Explanatory Study. Nutrients, 2021, 13, 3665.	1.7	14
907	Omegaâ€3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with nonâ€alcoholic fatty liver disease. FASEB Journal, 2021, 35, e21976.	0.2	11
908	Dementia and the Risk of Periodontitis: A Population-Based Cohort Study. Journal of Dental Research, 2022, 101, 270-277.	2.5	43
909	FH ALERT: efficacy of a novel approach to identify patients with familial hypercholesterolemia. Scientific Reports, 2021, 11, 20421.	1.6	4
910	Low-Flow Polysulfone Hemodialysis Alters Lipoprotein Parameters, Paraoxonase Activity and <i>in Vitro</i> Incorporation of Phospholipids. Journal of Biophysical Chemistry, 2017, 08, 23-38.	0.1	0
911	The Tip of The Iceberg: Non-Calcified Coronary Plague and Epicardial Adipose Tissue. Arquivos Brasileiros De Cardiologia, 2017, 108, 383-385.	0.3	0
912	The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk. Arquivos Brasileiros De Cardiologia, 2017, 108, 518-525.	0.3	3
913	Discordant Lipid Pattern and Carotid Atherosclerotic Plaque. Importance of Remnant Cholesterol. Arquivos Brasileiros De Cardiologia, 2017, 108, 526-532.	0.3	6
914	Prevalence of Diet Atherogenicity and Coexistence of Lipid Disorders and Arterial Hypertension among 50-year-old Inhabitants of Wroclaw, Poland. Central European Journal of Public Health, 2017, 25, 15-21.	0.4	1
915	Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease. Oncotarget, 2018, 9, 9489-9497.	0.8	5
916	What has changed in treatment of patients with dyslipidemia?. Interni Medicina Pro Praxi, 2017, 19, 106-108.	0.0	0
917	SIGNS OF ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND CORONARY HEART DISEASE. Nauchno-Prakticheskaya Revmatologiya, 2017, 55, 382-387.	0.2	1
918	The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia. Annals of Translational Medicine, 2017, 5, 477-477.	0.7	0
919	Guest Editorial: Reducing Risk in Familial Hypercholesterolaemia and Severe Dyslipidaemia: Novel Drugs Targeting PCSK9. European Cardiology Review, 2018, 13, 7.	0.7	0
920	Drug Adherence with Cardiovascular Medicines: Statins and Aspirin. Updates in Hypertension and Cardiovascular Protection, 2018, , 199-217.	0.1	0

#	Article	IF	Citations
921	Obstacles to Optimal Lipid-Lowering Therapyã€€â€• Any Solution? â€•. Circulation Journal, 2018, 82, 948-950.	0.7	0
922	Comparative analysis of the lipid panel assay accuracy in nurse-collected and self-collected samples of capillary blood. Laboratornaya Sluzhba, 2018, 7, 18.	0.0	0
923	Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?. Annals of Translational Medicine, 2018, 6, 60-60.	0.7	0
924	NEW DRUGS FOR THE TREATMENT OF DYSLIPIDEMIA. Acta Medica Medianae, 2018, 57, 54-63.	0.0	0
925	Therapeutic Management of Dyslipidemia Patients at Very High Cardiovascular Risk (CARDIO TRACK): Protocol for the Observational Registry Study. JMIR Research Protocols, 2018, 7, e163.	0.5	1
926	Management of hyperlipidemia in very high and extremely high-risk patients in Croatia. Cardiologia Croatica, 2018, 13, 430-431.	0.0	0
927	The role of atorvastatin and ezetimibe in contemporary lipid-lowering therapy â€“ time for combination treatmen. Pediatria I Medycyna Rodzinna, 2018, 14, 361-368.	2.3	0
928	Should We Intensify Statin Management in ACS Patients with Very Low LDL Cholesterol Levels?. Journal of Lipid and Atherosclerosis, 2019, 8, 204.	1.1	0
929	Indices of lipid panel in patients with essential hypertension, complicated with hemorrhagic stroke, after an early recovery period. Environment & Health, 2019, , 10-16.	0.1	0
930	Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol. Journal of Lipid and Atherosclerosis, 2019, 8, 208.	1.1	2
931	Lipid analysis in an aging population. Aging, 2019, 11, 1073-1074.	1.4	0
932	Lipoprotein(a): the underutilized risk factor for cardiovascular disease. Global Cardiology Science & Practice, 2019, 2019, e201911.	0.3	0
933	Role of single nucleotide Đ¢786C polymorphism of endothelial NO-synthase gene after myocardial infarction with ST-segment elevation. UMJ Heart & Vessels, 2019, .	0.0	0
934	Tissue-Mimicking Materials for Cardiac Imaging Phantomâ€”SectionÂ1: From Conception to Materials Selection. Series in Bioengineering, 2020, , 3-33.	0.3	2
935	Emotional disturbances and unfavorable events after myocardial infarction with ST-segment elevation: a Â«caseâ€‰â€”â€‰controlÂ» study. Ukrainian Therapeutical Journal, 2019, .	0.0	0
936	Assessment of the degree of adherence of medical laboratories to KDIGO 2012 guideline for evaluation and management of CKD in Czechia and Slovakia. Biochemia Medica, 2019, 29, 522-530.	1.2	2
937	Hypercholesterolemia, Lipid-Lowering Strategies and Microcirculation. , 2020, , 253-269.		1
938	Efeitos dos flavonoides do cacau na prevenÃ§Ã£o e no tratamento de doenÃ§as cardiovasculares: uma revisÃ£o de literatura. Revista De Ciencias Medicas (Campinas): Journal of Medical Sciences, 2019, 28, 85.	0.3	0

#	Article	IF	Citations
939	Hyperlipidemia management in Slovakia: observational study. Vnitrni Lekarstvi, 2019, 65, 761-769.	0.1	0
940	New original scale ofÂprognosis ofÂadverse outcome after ST segment elevation myocardial infarction. UMJ Heart & Vessels, 2019, .	0.0	0
941	Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry. Cardiology Research, 2020, 11, 311-318.	0.5	1
942	Nut Consumption and Noncommunicable Diseases. , 2020, , 441-452.		0
943	Neutrophil Extracellular Traps in Atherosclerosis and Thrombosis. Handbook of Experimental Pharmacology, 2020, , 405-425.	0.9	9
946	The Utility of New Biomarker-based Predictive Model for Clinical Outcomes Among ST-elevation Myocardial Infarction Patients. Open Biomarkers Journal, 2020, 10, 23-37.	0.1	0
947	Influences of Weight Loss and Physical Exercise on Lipid Panel in Overweight Middle-Aged Men. Hormozgan Medical Journal, 2020, 24, .	0.0	1
948	Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. International Journal of Molecular Sciences, 2021, 22, 11687.	1.8	44
949	Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy. Advances in Therapy, 2022, 39, 314-327.	1.3	5
950	Association of remnant cholesterol with intra- and extra-cranial atherosclerosis in Chinese community population. Atherosclerosis Plus, 2021, 46, 20-20.	0.3	1
951	HIV and Dyslipidemia. Contemporary Cardiology, 2021, , 431-466.	0.0	0
952	The Low-Density Lipoprotein Cholesterol Hypothesis: An Update. Contemporary Cardiology, 2021, , 121-138.	0.0	0
953	The plasma lipidome of the Quaker parrot (Myiopsitta monachus). PLoS ONE, 2020, 15, e0240449.	1.1	7
954	Changes in Target Achievement Rates after Statin Prescription Changes at a Single University Hospital. Cardiovascular Prevention and Pharmacotherapy, 2020, 2, 103.	0.0	1
955	Changes in High-Density Lipoprotein Cholesterol and Risks of Cardiovascular Events: A Post Hoc Analysis from the PICASSO Trial. Journal of Stroke, 2020, 22, 108-118.	1.4	3
956	Management of Hyperlipidemia in Very High and Extreme Risk Patients in Croatia: an Observational Study of Treatment Patterns and Lipid Control. Acta Clinica Croatica, 2020, 59, 641-649.	0.1	1
957	Statin therapy and low-density lipoprotein cholesterol reduction after acute coronary syndrome: Insights from the United Arab Emirates. Heart Views, 2020, 21, 80.	0.1	0
958	Thyroid function in patients with type 1 diabetes mellitus and chronic kidney disease receiving renal replacement therapy. MÃ¬Å¾narodnij EndokrinologÃ¬Änij Å½urnal, 2020, 16, 10-18.	0.1	1

#	Article	IF	Citations
959	Cost-utility analysis of evolocumab in patients with ASCVD in Italy. Global & Regional Health Technology Assessment, 0, 8, 155-167.	0.2	0
960	Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography. Journal of Atherosclerosis and Thrombosis, 2020, 27, 1183-1207.	0.9	3
961	Impacto dos Ãndices AterogÃªnicos em Estenose do Enxerto de Veia Safena. Arquivos Brasileiros De Cardiologia, 2020, 115, 538-544.	0.3	5
962	Adherence to statin therapy in patients with high and very high cardiovascular risk in real clinical practice. SeÄenovskij Vestnik, 2020, 11, 38-48.	0.3	1
963	Subclinical emotional distress predicts 6-month clinical outcomes after ST-segment elevation myocardial infarction. Future Cardiology, 2020, 16, 457-467.	0.5	1
964	Aggressive therapy with statins in elderly and malnourished patients with acute myocardial infarction: is the right time to change?. Journal of Geriatric Cardiology, 2016, 13, 815-816.	0.2	3
965	Prediction of Lifetime Risk of Cardiovascular Disease Deaths Stratified by Sex in the Japanese Population. Journal of the American Heart Association, 2021, 10, e021753.	1.6	4
966	Management of dyslipidemia in Poland: Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The Fourth Declaration of Sopot. Cardiology Journal, 2022, 29, 1-26.	0.5	4
967	Association Between Plasma Trimethyllysine and Prognosis of Patients With Ischemic Stroke. Journal of the American Heart Association, 2021, 10, e020979.	1.6	6
968	Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study. Advances in Therapy, 2022, 39, 504-517.	1.3	8
969	Atheroprotective Effects and Molecular Mechanism of Berberine. Frontiers in Molecular Biosciences, 2021, 8, 762673.	1.6	8
970	Familial Dyslipidemias. , 2021, , 1778-1782.		0
971	Prevalence of statin intolerance: a meta-analysis. European Heart Journal, 2022, 43, 3213-3223.	1.0	151
972	Lipoprotein (a)-mediated vascular calcification: population-based and in vitro studies. Metabolism: Clinical and Experimental, 2022, 127, 154960.	1.5	13
973	The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Cardiovascular Journal of Africa, 2020, 31, 25-31.	0.2	2
974	Risk Factor Clusters and Cardiovascular Disease in High-Risk Patients: The UCC-SMART Study. Global Heart, 2021, 16, 85.	0.9	6
975	The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. , 2021, 12, 1857.		2
976	Nutraceuticals in Paediatric Patients with Dyslipidaemia. Nutrients, 2022, 14, 569.	1.7	10

#	Article	IF	Citations
977	Cardiovascular risk prediction equations underestimate risk in people living with HIV: Comparison and cut-point redefinition for 19 cardiovascular risk equations. Current HIV Research, 2022, 20, .	0.2	1
978	Hydroethanolic Extract of Prunus domestica L.: Metabolite Profiling and In Vitro Modulation of Molecular Mechanisms Associated to Cardiometabolic Diseases. Nutrients, 2022, 14, 340.	1.7	12
979	Paradoxical Association Between Baseline Apolipoprotein B and Prognosis in Coronary Artery Disease: A 36,460 Chinese Cohort Study. Frontiers in Cardiovascular Medicine, 2022, 9, 822626.	1.1	1
980	Statin indication according to the 2019 World Health Organization cardiovascular disease risk charts and carotid ultrasound in Mexican mestizo rheumatoid arthritis patients. Advances in Rheumatology, 2022, 62, 4.	0.8	2
981	Nutraceuticals for Dyslipidaemia and Glucometabolic Diseases: What the Guidelines Tell Us (and Do) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	E.7	9
982	Triglyceride/low-density-lipoprotein cholesterol ratio is the most valuable predictor for increased small, dense LDL in type 2 diabetes patients. Lipids in Health and Disease, 2022, 21, 4.	1.2	14
983	EstÃ¡ndares SEA 2022 para el control global del riesgo cardiovascular. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2022, 34, 130-179.	0.4	11
984	Abnormal expression of long non-coding RNA rhabdomyosarcoma 2-associated transcript (RMST) participates in the pathological mechanism of atherosclerosis by regulating miR-224-3p. Bioengineered, 2022, 13, 2648-2657.	1.4	2
985	Discriminative Utility of Apelin-to-NT-Pro-Brain Natriuretic Peptide Ratio for Heart Failure with Preserved Ejection Fraction among Type 2 Diabetes Mellitus Patients. Journal of Cardiovascular Development and Disease, 2022, 9, 23.	0.8	3
986	Efficacy and safety of Qushi Huayu granule for hyperlipidemia: study protocol for a randomized, double-blind, placebo-controlled trial. Trials, 2022, 23, 104.	0.7	0
987	A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation. Journal of Personalized Medicine, 2022, 12, 206.	1.1	3
988	Genetic Lipid Disorders Associated with Atherosclerotic Cardiovascular Disease. Medical Clinics of North America, 2022, 106, 325-348.	1.1	3
989	Atherosclerosis: Pathogenesis and Key Cellular Processes, Current and Emerging Therapies, Key Challenges, and Future Research Directions. Methods in Molecular Biology, 2022, 2419, 3-19.	0.4	9
991	Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 447-460.	1.8	21
992	Influence of cholesterol level on long-term survival and cardiac events after surgical coronary revascularization. JTCVS Open, 2022, , .	0.2	4
993	Identification of the Chinese Population That Can Benefit Most From Postprandial Lipid Testing: Validation of the Use of Oral Fat Tolerance Testing in Clinical Practice. Frontiers in Endocrinology, 2022, 13, 831435.	1.5	4
994	Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8Âmmol/L. Angiology, 2022, , 000331972210758.	0.8	0
995	Achievement of European Society of Cardiology/European Atherosclerosis Society lipid targets in very high-risk patients: Influence of depression and sex. PLoS ONE, 2022, 17, e0264529.	1.1	1

#	Article	IF	Citations
997	A Bibliometric Analysis of Familial Hypercholesterolemia From 2011 to 2021. Current Problems in Cardiology, 2023, 48, 101151.	1.1	13
998	Roles of Cardiometabolic Factors in Mediating the Causal Effect of Type 2 Diabetes on Cardiovascular Diseases: A Two-Step, Two-Sample Multivariable Mendelian Randomization Study. Frontiers in Cardiovascular Medicine, 2022, 9, 813208.	1.1	11
999	Interaction Analysis of Abnormal Lipid Indices and Hypertension for Ischemic Stroke: A 10-Year Prospective Cohort Study. Frontiers in Cardiovascular Medicine, 2022, 9, 819274.	1.1	2
1000	Cardiac allograft vasculopathy in a long-term follow-up after heart transplantation: Role of remnant cholesterol in residual inflammation. Cardiology Journal, 2022, 29, 782-790.	0.5	3
1001	Age- and Diet-Dependent Changes in Hepatic Lipidomic Profiles of Phospholipids in Male Mice: Age Acceleration in Cyp2b-Null Mice. Journal of Lipids, 2022, 2022, 1-17.	1.9	6
1002	Cardiovascular event rate and death in highâ€risk secondary prevention patient cohort in Finland: A registry study. Clinical Cardiology, 2022, 45, 342-351.	0.7	8
1003	Association between changes in lipid indexes and early progression of kidney dysfunction in participants with normal estimated glomerular filtration rate: a prospective cohort study. Endocrine, 2022, , 1.	1.1	3
1004	Stepâ€byâ€step diagnosis and management of the nocebo/drucebo effect in statinâ€associated muscle symptoms patients: a position paper fromthe International Lipid Expert Panel(ILEP). Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1596-1622.	2.9	35
1005	Association Between Carotid Atherosclerosis and Atrial Fibrillation, Cardiac, and Renal Function. European Journal of Vascular and Endovascular Surgery, 2022, , .	0.8	7
1006	Prevalence and Mortality of Moderate or Severe Mitral Regurgitation Among Patients Undergoing Percutaneous Coronary Intervention With or Without Heart Failure: Results From CIN Study With 28,358 Patients. Frontiers in Cardiovascular Medicine, 2022, 9, 796447.	1.1	0
1007	Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines. Diabetes and Metabolism Journal, 2022, 46, 464-475.	1.8	8
1008	GuÃa de prÃ¡ctica clÃnica mexicana para el diagnÃ³stico y tratamiento de las dislipidemias y enfermedad cardiovascular ateroscleroÃ³tica. Archivos De Cardiologia De Mexico, 2022, 92, 1-62.	0.1	2
1009	Factors Affecting Mortality of Critical Limb Ischemia 1 Year after Endovascular Revascularization in Patients with Type 2 Diabetes Mellitus. Review of Diabetic Studies, 2022, 18, 20-26.	0.5	1
1010	A Heterozygous LMF1 Gene Mutation (c.1523C>T), Combined With an LPL Gene Mutation (c.590G>A), Aggravates the Clinical Symptoms in Hypertriglyceridemia. Frontiers in Genetics, 2022, 13, 814295.	1.1	1
1011	Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019. ClinicoEconomics and Outcomes Research, 2022, Volume 14, 189-203.	0.7	11
1012	Comparison of plasma separation using centrifugation or filtration for MONET lipoprotein apheresis in patients with cardiovascular disease and severe dyslipidemia. Therapeutic Apheresis and Dialysis, 2022, 26, 1281-1288.	0.4	3
1013	Aortic Pressure Levels and Waveform Indexes in People Living With Human Immunodeficiency Virus: Impact of Calibration Method on the Differences With Respect to Non-HIV Subjects and Optimal Values. Frontiers in Cardiovascular Medicine, 2021, 8, 772912.	1.1	4
1014	Age-related blood biochemical changes (lipid metabolism) in healthy young and mature men living under the North conditions. Klinicheskeskaya Laboratornaya Diagnostika, 2021, 66, 728-732.	0.2	0

#	Article	IF	Citations
1015	Comparison of High-Statin Therapy vs Moderate-Statin Therapy in Achieving Positive Low-Density Lipoprotein Change in Patients After Acute Coronary Syndrome: A Randomized-Control Trial. Cureus, 2021, 13, e20710.	0.2	0
1017	Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved?. Wiener Klinische Wochenschrift, 2022, 134, 294-301.	1.0	8
1018	Clinical Impact and Prognostic Role of Triglyceride to High-Density Lipoprotein Cholesterol Ratio in Patients With Chronic Coronary Syndromes at Very High Risk: Insights From the START Study. Frontiers in Cardiovascular Medicine, 2022, 9, 874087.	1.1	3
1019	Red yeast rice: a functional food used to reduce hyperlipidemia. Food Reviews International, 2023, 39, 4965-4991.	4.3	1
1021	Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global Cases. Advances in Therapy, 2022, 39, 3042-3057.	1.3	14
1022	Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ, The, 2022, 376, e067731.	3.0	14
1027	Social inequality and diabetes mellitus - developments over time among the adult population in Germany.. , 2019, 4, 11-28.		2
1028	Nephropathy in type 2 diabetics : predictive factors and evolving aspects.. Tunisie Medicale, 2021, 99, 466-474.	0.2	0
1029	Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease. Frontiers in Endocrinology, 2022, 13, 860698.	1.5	0
1030	Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis. Cardiology Research and Practice, 2022, 2022, 1-13.	0.5	11
1031	Association Between Lipoprotein(a) and Calcific Aortic Valve Disease: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 877140.	1.1	10
1032	New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease. Biomedicines, 2022, 10, 970.	1.4	8
1033	Is there any association between plasma lipid profile and severity of COVID-19?. Clinical Nutrition ESPEN, 2022, , .	0.5	1
1034	Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group. Atherosclerosis, 2022, 349, 233-239.	0.4	9
1035	Undertreatment or Overtreatment With Statins: Where Are We?. Frontiers in Cardiovascular Medicine, 2022, 9, 808712.	1.1	9
1037	Recent Advances on Familial Hypercholesterolemia in Children and Adolescents. Biomedicines, 2022, 10, 1043.	1.4	10
1038	Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK. BMJ Open, 2022, 12, e055015.	0.8	0
1039	Physiciansâ€™ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes. Cardiovascular Diabetology, 2022, 21, 57.	2.7	10

#	Article	IF	Citations
1040	Sex Differences in Characteristics, Treatments, and In-hospital Outcomes of Patients Undergoing Coronary Angiography or Intervention. Frontiers in Cardiovascular Medicine, 2022, 9, 878566.	1.1	6
1041	Assessment of the appropriateness of cardiovascular preventive medication in older people: using the RAND/UCLA Appropriateness Method. BMC Geriatrics, 2022, 22, 394.	1.1	1
1042	Regulation of the macrophage-related inflammatory micro-environment for atherosclerosis treatment and angiogenesis via anti-cytokine agents. Nano Research, 2022, 15, 7342-7354.	5.8	5
1043	FAMILIAL DYSBETALIPOPROTEINEMIA (TYPE III HYPERLIPOPROTEINEMIA). Eurasian Heart Journal, 2019, , 42-52.	0.2	1
1044	Terapia Hormonal e HipertensÃ£o em Mulheres na PÃ³s-Menopausa: Resultados do Estudo Longitudinal de SaÃºde do Adulto (ELSA-Brasil). Arquivos Brasileiros De Cardiologia, 2022, 118, 905-913.	0.3	2
1045	Nutrient Intake and Nutrition Status in Vegetarians and Vegans in Comparison to Omnivores - the Nutritional Evaluation (NuEva) Study. Frontiers in Nutrition, 2022, 9, .	1.6	21
1046	Serum Levels of Irisin Predict Cumulative Clinical Outcomes in Heart Failure Patients With Type 2 Diabetes Mellitus. Frontiers in Physiology, 2022, 13, .	1.3	7
1047	Attainment of Lipid Targets Following Coronary Artery Bypass Graft Surgery: Can We Do Better?. Journal of Lipid and Atherosclerosis, 2022, 11, 187.	1.1	4
1048	Lack of Awareness of Own Hypercholesterolemia or Statin Medication among Adult Statin Users in the United States: Prevalence and Patient Characteristics in a Repeated Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 6099.	1.2	0
1049	High Normal Urinary Albuminâ€“Creatinine Ratio Is Associated With Hypertension, Type 2 Diabetes Mellitus, HTN With T2DM, Dyslipidemia, and Cardiovascular Diseases in the Chinese Population: A Report From the REACTION Study. Frontiers in Endocrinology, 2022, 13, .	1.5	8
1050	Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis. Frontiers in Molecular Biosciences, 2022, 9, .	1.6	16
1051	Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada. Advances in Therapy, 2022, 39, 3262-3279.	1.3	7
1052	Impact of concomitant fibrates on immunotherapy outcomes for advanced <scp>nonâ€small</scp> cell lung cancer. Cancer Medicine, 2023, 12, 358-367.	1.3	5
1053	Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial. Trials, 2022, 23, .	0.7	0
1054	Association Between Plasma Vitamin D2 and Type 2 Diabetes Mellitus. Frontiers in Endocrinology, 2022, 13, .	1.5	4
1055	Alpha-lipoic acid administration affects psychological status and markers of inflammation and oxidative damage in patients with type 2 diabetes and coronary heart disease. Journal of Diabetes and Metabolic Disorders, 0, , .	0.8	0
1056	Demographics and Characteristics of Patients Admitted With Acute Coronary Syndrome to the Coronary Care Unit at King Abdulaziz University. Cureus, 2022, , .	0.2	1
1057	Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens. Open Forum Infectious Diseases, 2022, 9, .	0.4	8

#	Article	IF	Citations
1058	The promising novel therapies for familial hypercholesterolemia. Journal of Clinical Laboratory Analysis, 2022, 36, .	0.9	12
1059	Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies. PLoS ONE, 2022, 17, e0264563.	1.1	4
1060	Arterial stiffness in patients with type 1 diabetes and its comparison to cardiovascular risk evaluation tools. Cardiovascular Diabetology, 2022, 21, .	2.7	9
1061	Oral fat tolerance testing identifies abnormal pancreatic <scp>Î²â€cell</scp> function and insulin resistance in individuals with normal glucose tolerance. Journal of Diabetes Investigation, 2022, 13, 1805-1813.	1.1	4
1062	Clinical Profile and Management of Patient Patients with Ischemic Heart Disease and/or Peripheral Artery Disease in Clinical Practice: The APALUSA Study. Journal of Clinical Medicine, 2022, 11, 3554.	1.0	2
1063	Oat nutritious meal has beneficial effect on lipid metabolism in type 2 diabetes mellitus: A 3-month randomized controlled trial. Journal of Functional Foods, 2022, 95, 105156.	1.6	3
1064	SEA 2022 standards for the comprehensive control of cardiovascular risk. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2022, 34, 130-179.	0.1	1
1065	Dietary Plant Sterols and Phytosterol-Enriched Margarines and Their Relationship with Cardiovascular Disease among Polish Men and Women: The WOBASZ II Cross-Sectional Study. Nutrients, 2022, 14, 2665.	1.7	11
1066	Risk assessment with gut microbiome and metabolite markers in NAFLD development. Science Translational Medicine, 2022, 14, .	5.8	50
1067	Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia. Journal of Clinical Medicine, 2022, 11, 3810.	1.0	2
1068	Should We Be Screening for Ischaemic Heart Disease Earlier in Childhood?. Children, 2022, 9, 982.	0.6	3
1069	Remnant Cholesterol and Its Visit-to-Visit Variability Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes: Findings From the ACCORD Cohort. Diabetes Care, 2022, 45, 2136-2143.	4.3	13
1070	Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE). Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
1071	Randomized, Double-Blind, Placebo-Controlled Trial to Test the Effects of a Nutraceutical Combination Monacolin K-Free on the Lipid and Inflammatory Profile of Subjects with Hypercholesterolemia. Nutrients, 2022, 14, 2812.	1.7	6
1072	Serial Changes in Coronary Plaque Formation Using CT Angiography in Patients Undergoing PCSK9-Inhibitor Therapy With 1-year Follow-up. Journal of Thoracic Imaging, 0, Publish Ahead of Print, .	0.8	0
1073	Intensity of and Adherence to Lipidâ€Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease. Journal of the American Heart Association, 2022, 11, .	1.6	13
1074	The DA VINCI study: is Ireland achieving ESC/EAS guidelineâ€"directed LDL-C goals?. Irish Journal of Medical Science, 2023, 192, 1077-1084.	0.8	3
1075	Detecting Familial hypercholesterolemia in children and adolescents: potential and challenges. Italian Journal of Pediatrics, 2022, 48, .	1.0	6

#	Article	IF	Citations
1076	A microRNA Signature for the Diagnosis of Statins Intolerance. International Journal of Molecular Sciences, 2022, 23, 8146.	1.8	2
1077	Lipid Parameters and Proprotein Convertase Subtilisin/Kexin Type 9 in Healthy Lebanese Adults. Metabolites, 2022, 12, 690.	1.3	0
1078	RecapsomaÂ®: A Novel Mixture Based on Bergamot, Ipomoea Batatas, Policosanol Extracts and Liposomal Berberine for the Treatment of Hypercholesterolemia. Life, 2022, 12, 1162.	1.1	4
1079	Tackling Atherosclerosis via Selected Nutrition. International Journal of Molecular Sciences, 2022, 23, 8233.	1.8	18
1080	Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
1081	Relationship between liver dysfunction, lipoprotein concentration and mortality during sepsis. PLoS ONE, 2022, 17, e0272352.	1.1	7
1082	The role of non-HDL cholesterol and atherogenic indices in predicting poor glycemic control among type 2 diabetic patients in Basrah, Iraq. Qatar Medical Journal, 2022, 2022, .	0.2	0
1083	Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study. Atherosclerosis Plus, 2022, 50, 10-16.	0.3	8
1084	Blood lipid levels and treatment following an acute coronary syndrome or coronary intervention â€“ Journey from hospital to cardiac rehabilitation. International Journal of Cardiology Cardiovascular Risk and Prevention, 2022, 15, 200145.	0.4	0
1085	The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study. European Journal of Clinical Pharmacology, 2022, 78, 1801-1811.	0.8	3
1086	The Malaysian HEalth and WellBeing AssessmenT (MyHEBAT) Study Protocol: An Initiation of a National Registry for Extended Cardiovascular Risk Evaluation in the Community. International Journal of Environmental Research and Public Health, 2022, 19, 11789.	1.2	4
1087	Association of Fish and Omega-3 Fatty Acid Intake with Carotid Intima-Media Thickness in Middle-Aged to Elderly Japanese Men and Women: The Toon Health Study. Nutrients, 2022, 14, 3644.	1.7	3
1088	Risk stratification and lipid evaluation in mexican patients, evidence of lipid and cardiovascular analysis in REMECAR. The mexican registry of cardiovascular diseases (REMECAR group). Atherosclerosis Plus, 2022, 50, 32-39.	0.3	0
1090	Significance of detailed hematological parameters as markers of arteriogenic erectile dysfunction. Andrology, 2022, 10, 1556-1566.	1.9	1
1091	Familial Hypercholesterolaemia in Children and Adolescents: Current and Future Perspectives. Current Pediatric Reviews, 2023, 19, 234-241.	0.4	4
1092	Discriminative Value of Serum Irisin in Prediction of Heart Failure with Different Phenotypes among Patients with Type 2 Diabetes Mellitus. Cells, 2022, 11, 2794.	1.8	6
1093	The effect of statins exposure during pregnancy on congenital anomalies and spontaneous abortions: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	2
1094	Network Metaâ€Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipidâ€Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Lowâ€Density Lipoprotein Cholesterol. Journal of the American Heart Association, 2022, 11, .	1.6	12

#	Article	IF	Citations
1095	Prevalence, characteristics, and respiratory arousal threshold of positional obstructive sleep apnea in China: a large scale study from Shanghai Sleep Health Study cohort. Respiratory Research, 2022, 23, .	1.4	11
1096	Evaluation of the effectiveness of non-drug methods of hypercholesterolemia treatment. Klinicheskaia Meditsina, 2022, 100, 288-291.	0.2	0
1097	Lipidic profiles of patients starting peritoneal dialysis suggest an increased cardiovascular risk beyond classical dyslipidemia biomarkers. Scientific Reports, 2022, 12, .	1.6	5
1098	The efficacy of Zingiber officinale on dyslipidaemia, blood pressure, and inflammation as cardiovascular risk factors: A systematic review. Clinical Nutrition ESPEN, 2022, 51, 72-82.	0.5	4
1099	Associations Between Life-Course Lipid Trajectories and Subclinical Atherosclerosis in Midlife. JAMA Network Open, 2022, 5, e2234862.	2.8	12
1100	Association between single nucleotide polymorphism SLCO1B1 gene and simvastatin pleiotropic effects measured through flow-mediated dilation endothelial function parameters. Therapeutic Advances in Cardiovascular Disease, 2022, 16, 175394472211323.	1.0	1
1101	Causal effects of genetically predicted type 2 diabetes mellitus on blood lipid profiles and concentration of particle-size-determined lipoprotein subclasses: A two-sample Mendelian randomization study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
1102	Clinical characteristics of sitosterolemic children with xanthomas as the first manifestation. Lipids in Health and Disease, 2022, 21, .	1.2	2
1103	Perioperative Management and Clinical Outcomes of Liver Transplantation for Children with Homozygous Familial Hypercholesterolemia. Medicina (Lithuania), 2022, 58, 1430.	0.8	1
1104	Do statins benefit low-risk population for primary prevention of atherosclerotic cardiovascular disease: A retrospective cohort study. Frontiers in Medicine, 0, 9, .	1.2	0
1105	Non-fasting changes of Hs-CRP level in Chinese patients with coronary heart disease after a daily meal. Scientific Reports, 2022, 12, .	1.6	0
1106	Phytosterols and Î³-Oryzanol as Cholesterol Solid Phase Modifiers during Digestion. Foods, 2022, 11, 3629.	1.9	0
1107	False versus True Statin Intolerance in Patients with Peripheral Artery Disease. Journal of Clinical Medicine, 2022, 11, 6619.	1.0	0
1108	Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy. Nutrients, 2022, 14, 4769.	1.7	4
1109	Safety of reâ€challenging adults with acute lymphoblastic leukemia with PEGâ€asparaginaseâ€induced severe hypertriglyceridemia when treated with a pediatricâ€inspired regimen. EJHaem, 0, , .	0.4	1
1110	Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus. Molecular Biomedicine, 2022, 3, .	1.7	2
1111	Development of Machine Learning Tools for Predicting Coronary Artery Disease in the Chinese Population. Disease Markers, 2022, 2022, 1-18.	0.6	0
1112	Effects of short-term exposure to gaseous pollutants on metabolic health indicators of patients with metabolic syndrome in Northwest China. Ecotoxicology and Environmental Safety, 2023, 249, 114438.	2.9	1

#	Article	IF	Citations
1113	Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics. Journal of Atherosclerosis and Thrombosis, 2022, , .	0.9	2
1114	Secondary Prevention in Lower Extremity Artery Disease Patients: Lipid-Lowering Therapy and Long-Term Guideline Adherence. Journal of Clinical Medicine, 2022, 11, 6838.	1.0	1
1115	Interplay between Myokine Profile and Glycemic Control in Type 2 Diabetes Mellitus Patients with Heart Failure. Diagnostics, 2022, 12, 2940.	1.3	4
1116	Knowledge of HbA1c and LDLâ€€ treatment goals, subjective level of diseaseâ€related informationÂand information needs in patients with atherosclerotic cardiovascular disease. Clinical Cardiology, 2023, 46, 223-231.	0.7	3
1117	Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data. Journal of Clinical Medicine, 2022, 11, 6825.	1.0	3
1118	Patterns of Dyslipidemia Among Acute Coronary Syndrome (ACS) Patients at a Tertiary Care Hospital in Lahore, Pakistan. Cureus, 2022, , .	0.2	0
1119	Recommended and observed statin use among U.S. adults â€“ National Health and Nutrition Examination Survey, 2011-2018. Journal of Clinical Lipidology, 2023, 17, 225-235.	0.6	3
1120	Obesity and related comorbidities in a large population-based cohort of subjects with type 1 diabetes in Catalonia. Frontiers in Endocrinology, 0, 13, .	1.5	2
1121	Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option. International Journal of Molecular Sciences, 2023, 24, 170.	1.8	5
1122	Therapeutics in Metabolic Diseases. Advances in Experimental Medicine and Biology, 2023, , 255-273.	0.8	0
1123	Fenofibrate for the prevention of progression of non-proliferative diabetic retinopathy: review, consensus recommendations and guidance for clinical practice. International Journal of Ophthalmology, 2022, 15, 2001-2008.	0.5	3
1124	Gender-associated cardiometabolic risk profiles and health behaviors in patients with type 2 diabetes: a cross-sectional analysis of the Joint Asia Diabetes Evaluation (JADE) program. The Lancet Regional Health - Western Pacific, 2023, 32, 100663.	1.3	1
1125	Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia. Journal of Thrombosis and Thrombolysis, 2023, 55, 263-272.	1.0	4
1126	Non-HDL-C and LDL-C/HDL-C are associated with self-reported cardiovascular disease in a rural West African population: Analysis of an array of lipid metrics in an AWI-Gen sub-study. PLoS ONE, 2022, 17, e0278375.	1.1	2
1127	Dietary Fat Intake among Chinese Adults and Their Relationships with Blood Lipids: Findings from China Nutrition and Health Surveillance and Comparison with the PURE Study. Nutrients, 2022, 14, 5262.	1.7	1
1128	The Relation between Resistin (â^'420C/G) Single Nucleotide Variant, Resistin Serum Concentration, Carbohydrate, and Lipid Parameters and Fried Food Taste Preference in Patients with Hypertriglyceridemia. Nutrients, 2022, 14, 5092.	1.7	2
1129	Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia. International Journal of Molecular Sciences, 2023, 24, 75.	1.8	20
1130	High prevalence of dyslipidaemia among persons with diabetes mellitus and hypertension at a tertiary hospital in Blantyre, Malawi. BMC Cardiovascular Disorders, 2022, 22, .	0.7	5

#	Article	IF	Citations
1131	Fibroblast growth factor 21 is an independent predictor of prevalent and incident obstructive sleep apnea. IScience, 2023, 26, 105985.	1.9	1
1132	Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions. Vascular Health and Risk Management, 0, Volume 19, 31-41.	1.0	0
1133	Prevalence of Diabetes and Its Association with Atherosclerotic Cardiovascular Disease Risk in Patients with Familial Hypercholesterolemia: An Analysis from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). Pharmaceuticals, 2023, 16, 44.	1.7	2
1134	Non-Alcoholic Fatty Liver Disease: Pathogenesis and the Significance of High-Density Lipoprotein as a Molecular Modifier. , 0, , .		0
1135	Low HDL-Cholesterol Concentrations in Lung Transplant Candidates are Strongly Associated With One-Year Mortality After Lung Transplantation. Transplant International, 0, 36, .	0.8	0
1136	Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease. Circulation Research, 2023, 132, 452-464.	2.0	12
1137	Far North residentsâ€™ age-related peculiarities based on construction of functional state matrices. Ekologiya Cheloveka (Human Ecology), 0, , .	0.2	0
1138	Association between total cholesterol and total bone mineral density in US adults: National Health and Nutrition Examination Survey (NHANES), 2011â€“2018. Journal of Orthopaedic Surgery and Research, 2023, 18, .	0.9	3
1139	The Italian Society of Andrology and Sexual Medicine (SIAMS), along with ten other Italian Scientific Societies, guidelines on the diagnosis and management of erectile dysfunction. Journal of Endocrinological Investigation, 2023, 46, 1241-1274.	1.8	13
1140	Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study. Diabetes and Metabolism Journal, 2023, 47, 59-71.	1.8	2
1141	Cardiovascular Outcomes according to Comorbidities and Low-Density Lipoprotein Cholesterol in Korean People with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2023, 47, 45-58.	1.8	7
1142	Remnant Cholesterol and Common Carotid Artery Intima-Media Thickness in Community Population with Normal Low-Density Lipoprotein Cholesterol. Cerebrovascular Diseases, 2023, 52, 487-494.	0.8	0
1143	Childhood Dyslipidemia and Carotid Atherosclerotic Plaque in Adulthood: The Cardiovascular Risk in Young Finns Study. Journal of the American Heart Association, 2023, 12, .	1.6	5
1144	Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules, 2023, 28, 969.	1.7	14
1145	Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis. European Journal of Epidemiology, 2023, 38, 485-499.	2.5	12
1146	How Did the Updated 2019 European Society of Cardiology/European Atherosclerosis Society Risk Categorization for Patients with Diabetes Affect the Risk Perception and Lipid Goals? A Simulated Analysis of Real-life Data from EPHESUS Study. Anatolian Journal of Cardiology, 2023, 27, 78-87.	0.5	1
1147	A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organization. International Journal of Stroke, 2023, 18, 499-531.	2.9	26
1148	Research Progress in the Clinical Treatment of Familial Hypercholesterolemia. Current Medicinal Chemistry, 2023, 30, .	1.2	1

#	Article	IF	Citations
1149	The U-shaped association of non-high-density lipoprotein cholesterol with all-cause and cardiovascular mortality in general adult population. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0
1150	Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome. Journal of Clinical Medicine, 2023, 12, 1481.	1.0	0
1151	Systematic Breakfast Consumption of Medium-Quantity and High-Quality Food Choices Is Associated with Better Vascular Health in Individuals with Cardiovascular Disease Risk Factors. Nutrients, 2023, 15, 1025.	1.7	3
1152	Plasma Apolipoprotein Concentrations Are Highly Altered in Severe Intensive Care Unit COVID-19 Patients: Preliminary Results from the LIPICOR Cohort Study. International Journal of Molecular Sciences, 2023, 24, 4605.	1.8	3
1153	Hypertriglyceridemia is associated with decline of estimated glomerular filtration rate and risk of end-stage kidney disease in a real-word Italian cohort: Evidence from the TG-RENAL Study. European Journal of Internal Medicine, 2023, 111, 90-96.	1.0	1
1154	Daily exercise improves the long-term prognosis of patients with acute coronary syndrome. Frontiers in Public Health, 0, 11, .	1.3	1
1155	Efficacy and Safety of Coadministered Ezetimibeâ€“Rosuvastatin plus Telmisartan in South Korean Patients with Dyslipidemia and Hypertension: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase III Trial. Journal of Clinical Medicine, 2023, 12, 2377.	1.0	1
1156	Impact of low-density lipoprotein cholesterol and lipoprotein(a) on mid-term clinical outcomes following coronary artery bypass grafting: A secondary analysis of the DACAB trial. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	2
1157	The Role of Î±-Linolenic Acid and Its Oxylipins in Human Cardiovascular Diseases. International Journal of Molecular Sciences, 2023, 24, 6110.	1.8	9
1158	Higher Levels of Blood Selenium are Associated with Higher Levels of Serum Lipid Profile in US Adults with CKD: Results from NHANES 2013â€“2018. Biological Trace Element Research, 0, , .	1.9	3
1159	Case Series of Genetically Confirmed Index Cases of Familial Hypercholesterolemia in Primary Care. American Journal of Case Reports, 0, 24, .	0.3	0
1160	Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial. EClinicalMedicine, 2023, 58, 101933.	3.2	2
1161	Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nature Reviews Cardiology, 2023, 20, 600-616.	6.1	22
1162	Short-Term Effect of Nutraceutical Fruit Juices on Lipid Metabolism in Patients with Acquired Hypercholesterolemia. International Journal of Molecular Sciences, 2023, 24, 7358.	1.8	0
1163	Soluble PCSK9 Inhibition: Indications, Clinical Impact, New Molecular Insights and Practical Approachâ€”Where Do We Stand?. Journal of Clinical Medicine, 2023, 12, 2922.	1.0	4
1164	A bibliometric analysis and visualization of literature on non-fasting lipid research from 2012 to 2022. Frontiers in Endocrinology, 0, 14, .	1.5	1
1168	Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen. Frontiers in Allergy, 0, 4, .	1.2	0
1177	Leptin and Obesity: Understanding the Impact on Dyslipidemia. , 0, , .		0

#	Article	IF	Citations
1183	Management of Cardiovascular Disease in the Elderly. , 2023, , 1-41.		0
1186	Management of Cardiovascular Disease in the Elderly. , 2024, , 343-383.		0
1187	Dyslipidemias. , 2023, , 145-161.		0